Hospital environments harbor chlorhexidine tolerant bacteria potentially linked to chlorhexidine persistence in the environment

- Jiaxian Shen¹, Yuhan Weng¹, Tyler Shimada¹, Meghana Karan¹, Andrew Watson¹, Rachel L.
 Medernach², Vincent B. Young³, Mary K. Hayden², Erica M. Hartmann^{1,4,5,*}
- ⁵ ¹Department of Civil and Environmental Engineering, McCormick School of Engineering,
- 6 Northwestern University, USA
- ²Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical
 Center, USA
- ⁹ ³Department of Internal Medicine/Division of Infectious Diseases, Department of Microbiology
- 10 & Immunology, University of Michigan Medical School, USA
- ⁴Center for Synthetic Biology, Northwestern University, USA
- ⁵Department of Medicine/Division of Pulmonary Medicine, Feinberg School of Medicine,
- 13 Northwestern University, USA
- 14 *Correspondence: Erica M. Hartmann; 2145 Sheridan Road, Tech A322, Evanston, IL 60208;
- 15 Email: erica.hartmann@northwestern.edu; Tel: 847-467-4528

16 Abstract

- 17 A One Health approach is essential in combating antibiotic and antimicrobial resistance.
- 18 Chlorhexidine (di)gluconate (CHG), a widely used antiseptic in medical intensive care units
- 19 (MICU), has recently come under scrutiny. However, studies on CHG tolerance, particularly in
- 20 interconnected indoor environments, are limited. We comprehensively explored CHG tolerance
- 21 in MICU environments from chemical, microbial, and molecular perspectives. Using microcosm
- 22 experiments and field surveys, we demonstrated that CHG, if transferred from patient skin to
- 23 environments, can persist on surfaces despite cleaning and disinfection and decrease to sublethal
- 24 levels for clinically relevant bacteria. We detected widespread CHG-tolerant bacteria (≥ 18.75
- 25 μg/mL), including opportunistic pathogens (e.g., *Pseudomonas aeruginosa, Stenotrophomonas*
- 26 *maltophilia*, *Elizabethkingia miricola*), with minimum inhibitory concentrations up to 512
- 27 µg/mL. Sink drains emerged as critical hotspots, and indoor air as a potential transport
- 28 mechanism. We observed indications of bacterial persistence, increased tolerance, in-situ
- 29 evolution, and dissemination across MICU rooms. Molecular analyses revealed heterogeneous
- 30 and largely unexplored CHG resistance mechanisms and identified resistance determinant
- 31 candidates, particularly *qacEdelta1*-carrying, plasmid-borne multidrug-resistant cassettes. Our
- 32 findings underscore the importance of understanding human-environment and chemical-microbe
- 33 interactions to preserve chlorhexidine's efficacy and inform infection prevention strategies. We
- 34 advocate for integrated environmental management and clinical interventions under the One
- 35 Health framework.

36 Introduction

- 37 The emergence of resistance to antimicrobials is a critical concern worldwide, severely limiting
- 38 our ability to prevent and treat infections. Chlorhexidine digluconate (CHG) has been widely
- 39 used as a topical antiseptic in hospitals), both for patient skin antisepsis and for healthcare
- 40 provider hand hygiene. Other clinical applications of CHG include antiseptic bathing of residents
- 41 of long-term care facilities, skin preparation before invasive outpatient procedures and surgeries,
- 42 and as a mouthwash for treating gingivitis. Additionally, it is extensively utilized in veterinary
- 43 medicine. Chlorhexidine has broad antimicrobial activity it is bactericidal at higher
- 44 concentrations (>0.12%) and bacteriostatic at lower concentrations $(0.02\%-0.06\%)^1$ and it has
- 45 been used for decades with little concern for resistance. While daily bathing of patients with 2%
- 46 $(20,000 \ \mu g/mL)$ CHG has served as an effective measure for prevention of healthcare-associated
- 47 infections²⁻⁴, exposure of bacteria to sublethal concentrations of chlorhexidine can lead to
- 48 reduced susceptibility to this antiseptic and other clinically relevant antibiotics (e.g.,
- 49 erythromycin, clindamycin, daptomycin, vancomycin, azithromycin and ciprofloxacin)⁵⁻⁸. Post-
- 50 application, CHG may be shed from the skin onto indoor surfaces, resulting in sublethal
- 51 concentrations of CHG in the patient's surrounding environment. Furthermore, CHG residuals
- 52 might persist in the built environment, even after undergoing degradation by heat, light, and
- 53 other chemicals⁹⁻¹¹.

54 Decreased susceptibility to CHG has been observed in various bacterial taxa (e.g., Acinetobacter

55 spp., *Pseudomonas* spp., *Enterobacter* spp., and *Enterococcus* spp.), including clinically

56 significant pathogens (e.g., *Klebsiella pneumoniae*, methicillin-resistant *Staphylococcus aureus*

- 57 [MRSA]). Cross-resistance of these isolates to colistin has also been observed, raising concerns
- 58 about unintended consequences of CHG application in healthcare settings¹²⁻¹⁴. Studies have
- 59 obtained correlations between CHG susceptibility and antibiotic susceptibility in both minimum
- 60 inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) among
- 61 Gram-negative bacteria, and MBCs among Gram-positive bacteria¹⁵. Sporadic cases of hospital
- 62 infection outbreaks caused by highly CHG-resistant *Serratia marcescens* strains have been
- 63 reported¹⁶⁻¹⁹. The concern is magnified considering the inductive effect of widely used
- 64 antimicrobial chemicals (e.g., triclosan, CHG) on the dissemination of antibiotic resistance genes
- $(ARGs)^{20,21}$, and the possibility that mobile antibiotic resistance elements could transfer from
- 66 environmental bacteria to human pathogens. In a veterinary hospital, multi-drug resistant
- 67 Serratia isolates with similar resistance profiles were detected from animals and CHG solutions
- 68 used across the hospital. Furthermore, the authors identified an IncHI2 multi-drug resistance
- 69 plasmid that is shared by these *Serratia* isolates and an *Enterobacter hormaechei* strain
- 70 previously recovered from the hospital environment, with the plasmid's mobility confirmed by
- 71 conjugation experiments¹⁹.

72 Generally, studies about CHG tolerance are restricted to human subjects (e.g., clinical isolates

- from patients, especially those on the WHO priority list of antibiotic-resistant bacteria), while
- 74 little attention has been paid to the surrounding environments, which can serve as hotspots of
- 75 antibiotic-resistant bacteria and hospital-acquired infections. To date, CHG susceptibility of
- reported only sporadically. These reports are often associated
- 77 with outbreak investigations^{19,22-24}, while comprehensive surveillance is lacking. Comprehensive
- 78 CHG surveillance is partly impeded by the lack of standardized terms, including resistance,
- tolerance, and reduced susceptibility. In this study, we defined chlorhexidine resistance using
- 80 epidemiological cut-off values proposed previously (Table S1)^{12,25,26}, due to the lack of
- 81 standardized clinical breakpoints for chlorhexidine²⁷. The values were defined as the upper limit
- 82 of the normal MIC distribution for a given antimicrobial and wild-type species. Clinical
- 83 implications of these values are unclear, but they are nevertheless helpful in resistance
- 84 monitoring. In cases where epidemiological cut-offs are also unknown, we interchangeably used
- 85 the terms tolerance and reduced susceptibility as general descriptors. In this study, chlorhexidine
- 86 digluconate was used for MIC measurements, and chlorhexidine MICs were used as a general
- 87 term for MICs reported by previous studies where the chemical was not explicitly stated. In cases
- 88 where the taxonomy or the epidemiological cut-off values were unknown, for uniformity
- reasons, we described MICs \geq 128 µg/mL as high CHG MICs, MICs of 512 µg/mL as the
- 90 highest CHG MICs, and bacteria that grew at 18.75 μg/mL CHG as CHG tolerant³.
- 91 In this study, we conducted the most comprehensive exploration of CHG tolerance in MICU
- 92 environments to date, examining chemical, microbial, and molecular aspects. Through controlled
- 93 microcosm experiments, we gained insights into the fate of CHG on surfaces and the factors
- 94 influencing its persistence. In subsequent field surveys, we identified environmental hotspots
- 95 harboring CHG-tolerant, opportunistic, persistent, and disseminating bacteria. Additionally, we
- 96 identified candidate and novel ARGs and mobile genetic cassettes potentially associated with
- 97 CHG tolerance.

98 Results


99 Residual chlorhexidine persists on surfaces under disinfection and cleaning in

100 microcosm experiments

- 101 CHG in the environment can degrade naturally due to environmental factors such as heat and
- 102 light. Additionally, physical removal through cleaning or reactions with cleaning products may
- 103 decrease residual surface concentrations. We investigated CHG persistence on three common
- 104 hospital surface types laminate wood, plastic (high-density polyethylene; HDPE), and metal
- 105 (stainless steel) under six cleaning practices. These practices included no cleaning, cleaning

with water, and disinfecting with ethanol, bleach, peracetic acid, or benzalkonium chloride (Fig.S1).

- 108 While the concentration of CHG decreased over time, it persisted on indoor surfaces over 24 h
- 109 (Fig. 1a, Table S2). The persistence patterns of CHG residual were impacted by surface material
- 110 and cleaning practice. We first investigated the immediate impact of wiping a surface on CHG
- 111 persistence by comparing the concentrations at time 0 (i.e., the amount applied) and 10 min (i.e.,
- 112 0.17 h). Among the cleaning practices, wiping with peracetic acid had the largest immediate
- 113 impact, showing significant differences on plastic and laminate wood surfaces (p < 0.02) and
- approaching significance on metal surfaces (p = 0.056). This is supported by previous evidence
- 115 that CHG can be inactivated at a low pH and in the presence of anionic molecules²⁸⁻³⁰. In
- 116 contrast, none of the other disinfectants tested are known to interact with CHG. Benzalkonium
- 117 chloride and ethanol have been shown to have synergistic or additive antimicrobial properties
- 118 when applied with CHG, indicating that their co-occurrence will not cause chlorhexidine
- degradation³¹⁻³⁵. This is concordant with our observation that CHG concentration is not
- 120 significantly affected by benzalkonium chloride or ethanol application.
- 121 Although CHG concentration significantly decreased after 24 h on all cleaned surfaces, it still
- persisted on indoor surfaces with residual concentrations ranging from 7.0 to 12.3 μ g/cm² (Fig.
- 123 1a). When cleaning was not conducted, CHG concentrations remained stable on laminate wood
- and plastic surfaces, whereas a significant decrease was observed on metal surfaces (p = 0.005).
- 125 While all cleaning methods induced significant concentration reductions after 24 h (Fig. 1a),
- 126 only cleaning plastic and laminate wood showed a significantly greater reduction effect than no
- 127 cleaning (p < 0.05), whereas disinfecting did not statistically differ from cleaning with water
- 128 (Fig. 1b). This suggests that, for all tested surface types, potential interactions between
- 129 disinfecting chemicals and CHG do not exhibit a notably greater reduction effect than the
- 130 physical removal of CHG during cleaning. Our findings align with previous indications that
- 131 chlorhexidine degradation might be catalyzed by metals and that chlorhexidine is unstable under
- 132 acidic and alkaline conditions (pH 3.5-6.5 and pH > 8.5)³⁶.



134 Fig. 1 Residual CHG persists on surfaces despite cleaning and disinfection, with

- 135 concentrations decreasing to sublethal levels for clinically relevant bacteria. a) The change
- 136 patterns of CHG concentrations on surfaces over time in response to cleaning and disinfection.
- 137 Significance was determined by paired *t*-tests with the alternative hypothesis that the CHG
- concentration at 0 h was greater than that at 0.17 h (or 24 h). For the immediate impact (0 h vs
 0.17 h), only groups with significant differences were labeled for visual clarity. Recovery rates in
- sampling and measurement were accounted for in the calculations. **b)** Immediate and long-term
- reduction effects of cleaning practices across surface types. Significance was determined by
- 142 pairwise *t*-tests relative to the "no cleaning" group or the "cleaning with water" group, with the
- 143 alternative hypothesis that the tested groups had a greater reduction effect than the reference
- 144 group. Multi-test *p*-values were adjusted using the Benjamini-Hochberg method. Only significant
- 145 associations were labeled; thus, only cleaning plastic and laminate wood showed a significantly
- 146 greater reduction effect than no cleaning. c) Clinically relevant bacteria can survive 24-hour
- 147 exposure to CHG residual concentrations on plastic surfaces.

148 Clinically relevant bacteria can survive 24 h low-dose chlorhexidine exposure on

149 surfaces

- 150 We examined the survival of four clinically relevant bacterial isolates (*Escherichia coli* [ATCC
- 151 25922], Klebsiella pneumoniae [ATCC 13883], Klebsiella variicola [20-20012]³⁷,
- 152 Staphylococcus aureus [ATCC 29213]) on plastic surfaces after exposure to CHG for 24 h (Fig.
- 153 1c). Plastic was selected as a representative surface because it is a common material of
- 154 equipment in the immediate vicinity of patients and healthcare workers (e.g., bedrail, nurse call
- button, keyboard, mouse). Five concentrations of CHG (31.00, 15.50, 3.10, 0.31, and $0 \mu g/cm^2$)
- 156 were tested to encompass the range persisting on surfaces after cleaning or disinfection.
- 157 After 24 h, all species of bacteria survived on CHG-treated surfaces across all tested microbial
- densities and CHG concentrations $(2.58 1.28 \times 10^6 \text{ CFU/cm}^2, \log_{10} \text{ reduction ranging from } 0.08$
- to 4.87). Although fewer *Klebsiella pneumoniae* CFUs survived at 15.5 and 31 μg/cm² CHG, an
- 160 estimation from the data trend suggests that >17 CFU/cm² could survive at CHG concentrations
- 161 of 8.4-11.5 µg/cm² (range of CHG persisting on plastic surfaces). As previous studies have linked
- 162 exposure to sublethal concentrations of chlorhexidine with reduced susceptibility to chlorhexidine
- 163 and clinical antibiotics such as vancomycin and daptomycin^{6-8,38}, these results raise concerns about
- 164 potential development of antimicrobial resistance in bacteria on surfaces that possibly harbor CHG
- 165 residues (e.g., hospital environments where patients are bathed with CHG).

166 Chlorhexidine-tolerant bacteria are widespread in MICU environments with sink

167 drains being critical hotspots

- 168 Our microcosm experiments indicated that the environment may serve as a hotspot for CHG-
- 169 tolerant bacteria. To determine how widespread CHG tolerance is *in situ*, we further conducted a
- 170 field survey of environmental locations in a MICU (Methods, Fig. S2). Cultivation yielded a
- total of 1415 isolates of 345 different phenotypic morphologies, of which 306 isolates (21.6%)


- 172 were confirmed to grow at 18.75 μ g/mL CHG at 25 °C (Fig. S3). In this study, 18.75 μ g/mL was
- used as the threshold to describe CHG tolerance of bacteria³. Additionally, 203 isolates (14.3%)
- 174 were suspected to grow; due to colony proximity on the agar, it was difficult to determine
- 175 whether they grew independently or were protected by neighboring colonies. All 509 isolates
- 176 (36.0%) underwent CHG MIC testing.

177 We found that unit area surface bioburden in the MICU was significantly associated with touch

- 178 and cleaning frequencies (see Methods for definitions of touch frequencies), and the overall trend
- 179 was consistent with a previous study³⁹. The rarely cleaned doorsills had significantly higher
 180 bioburden than high-touch bedrails and nurse call buttons, followed by medium-touch keyboards
- (unpaired *t*-tests, \log_{10} scale) (Fig. 2a). This trend was also consistent for the absolute bioburden
- 182 in the entirety of the surfaces (Fig. S4). The absolute bioburden on low-touch light switches was
- 183 the lowest. However, they exhibited the highest unit area bioburden among dry surfaces. It is
- 184 worth noting that the switches had the smallest surface area (Table S3), which may have
- 185 contributed to greater uncertainty in calculating the unit area bioburden. No effect of sampling
- 186 seasons and patient room isolation status (contact isolation or not) was observed (Fig. S5).
- 187 Despite CHG primarily being applied to patient skin, CHG tolerance was identified in multiple
- 187 Despite erro primarry being applied to patient skin, erro tolerance was identified in induple
- 188 spatially distinct locations within the MICU. Most bacteria on dry surfaces were not CHG
- tolerant at 25°C (Fig. 2b), defined as the ability to grow at 18.75 μ g/mL CHG. The percentages
- 190 of bacteria exhibiting tolerance did not significantly differ among dry surfaces, with mean
- 191 percentages ranging from 0% (keyboards in patient rooms, light switches in the hallway) to
- 192 13.2% (nurse call buttons). Potential pathogens (as indicated by β hemolysis on blood agar at
- 193 37 °C) were detected across all environmental locations⁴⁰. However, doorsills were the only dry
- 194 surfaces where CHG tolerance at 37 °C was detected (Fig. 2c, 32 µg/mL one isolate, 64 µg/mL
- 195 four isolates). There was also a slight trend of a subpopulation of doorsill samples harboring
- 196 high proportions of CHG tolerant bacteria (3 out of 59 samples had percentages >90%).

197 Sink drains were critical hotspots for absolute bioburden (Fig. S4), CHG tolerance (Fig. 2b-c),

- and potential pathogens (Fig. 2c). The absolute bioburden and proportion of CHG-tolerant
- bacteria in sink drains were significantly higher than on all dry surfaces ($p \le 0.0001$). Moreover,
- 200 37 bacterial isolates with high CHG MICs ($\geq 128 \ \mu g/mL$) were detected from sink drains in
- 201 patient rooms, medication rooms, and MICU hallways (128 µg/mL 17 isolates, 256 µg/mL 10
- 202 isolates, 512 μg/mL 10 isolates) (Fig. 2c). Of the CHG-tolerant bacteria at 25 °C from the sink
- 203 drains, 70.6% (127 out of 180 isolates) were β -hemolytic (a highly predictive indication of
- 204 pathogenicity⁴⁰), including these with high MICs (24 out of 29 isolates, Fig. 2c).



205

Fig. 2 Chlorhexidine-tolerant bacteria are widespread in MICU environments with sink

207 drains being critical hotspots. a) Unit area bioburden of bacteria across different touch

208 frequencies on dry surfaces (cultivation temperature: 25 °C). CFU: colony forming unit. To

- 209 avoid mis-interpreting data with small colony counts, we set the limit of quantification (LOQ) of
- 210 our culture efforts as colony counts = 3. Values below this threshold were recorded as half of
- LOQ (i.e., 1.5). b) Proportion of bacteria tolerant to 18.75 µg/mL CHG (described as CHG
- tolerant in this study) at 25 °C across different touch frequencies on dry surfaces and sink. The
- 213 proportion of sink samples was significantly higher than that of all the other touch groups
- according to unpaired *t*-tests ($p \le 0.0001$ for all comparisons). In both a) and b), only significant
- 215 comparisons were labeled for visual clarity. c) Of the bacterial isolates growing at 18.75 μ g/mL
- 216 CHG at 25 °C, distribution of their CHG MICs at 37 °C and the corresponding blood hemolysis
- 217 status. Nurse call button is abbreviated as nurse call in the figure.

Opportunistic pathogens and high CHG MIC bacteria were detected in MICU environments with increased tolerance and potential for persistence

220 To further investigate their potential clinical importance and genomic resistance mechanisms, we 221 performed whole-genome sequencing on 63 isolates (Fig. S6, Table S4). The isolates were 222 randomly selected, with efforts to ensure coverage of various colony morphologies and MICs. 223 Additionally, comparisons were prioritized by selecting isolates with different MICs but the 224 same colony morphology. Among these, the three most represented species are opportunistic 225 pathogens: *Stenotrophomonas maltophilia* (n = 19), *Elizabethkingia miricola* (n = 7), and 226 *Pseudomonas aeruginosa* (n = 6). Isolates with high CHG MICs were detected among these 227 species, with the highest values being 128, 512, and 128 µg/mL, respectively. Notably, all these 228 isolates were recovered from sink drains located in diverse spaces across patient rooms, 229 medication rooms, and hallways, except for one S. maltophilia isolate from a doorsill in the 230 hallway. Additionally, we detected two Acinetobacter radioresistens isolates from the doorsill of 231 a patient room, both carrying the carbapenemase gene bla_{OXA-23} . While there were no patient 232 infections or colonization by S. maltophilia or E. miricola at the sampled MICU during the 233 sampling sessions, these species have previously been reported to develop multi-drug resistance 234 and be associated with nosocomial and community-acquired infections. Specifically, S. *maltophilia* is associated with respiratory infections⁴¹. E. miricola has been reported to associate 235 236 with a variety of infections including bacteremia, pulmonary abscess, urinary tract infection, catheter-associated bacteremia in a hemodialysis patient, and a fatal intracranial infection⁴²⁻⁴⁹. 237 238 Elizabethkingia has also been implicated in healthcare-associated outbreaks of the built healthcare environment⁵⁰. *P. aeruginosa* can cause pneumonia and bacteremia, along with 239 urinary tract and wound infections⁵¹. It is one of the three species ranked first priority on the 240 World Health Organization (WHO) list of antibiotic-resistant bacteria⁵² and a pathogen of major 241 242 concern for nosocomial infections⁵³. Although rare, A. radioresistens can cause infections in the lungs, blood, wounds, or urinary tracts, particularly in hospital settings⁵⁴⁻⁵⁷. More importantly, it 243 244 has been identified as a potential disseminator of ARGs, transferring the *bla*_{OXA-23} gene to Acinetobacter baumannii⁵⁸, another first-priority pathogen on the WHO list. 245


Moreover, we identified five genomically different isolates belonging to novel species according to multiple identification algorithms (KmerFinder, PhyloPhlAn, autoMLST, and MiGA), all of which were recovered from sink drains and three of which are potential pathogens (β -hemolysis on blood agar⁴⁰) harboring multiple copies of multidrug-resistant ARGs. Three can be identified to genus level (*g Stenotrophomonas*, *g Achromobacter*, *g Cupriavidus*), while the other two

251 can only be identified to family level (*f Rhizobiaceae*, *f Xanthomonadaceae*).

252 Interestingly, in this subgroup (63 out of 1415 isolates), we observed potential evidence of 252 hostorial paraistance and in gits evaluation of appartunistic natherange in gink drains, as well as

254 their potential dissemination across multiple MICU rooms. In both sampling events (February and July), we recovered the same strains (ANI \geq 99.99%^{59,60}) of *P. aeruginosa* and *S.* 255 256 *maltophilia* from the same sink drains across three patient rooms (PT 3, PT 4, PT 8, Fig. 3a). 257 Observation of the same strain in the same location at two time points suggests that it persisted in 258 sink drains over the course of half a year. Notably, the original *P. aeruginosa* isolate and one of 259 the subsequent isolates carried type-1 *qacEdelta1*-carrying plasmids and exhibited high CHG 260 MICs (128 µg/mL, above *P. aeruginosa*'s epidemiological breakpoint 50 µg/mL, Fig. 6, Table 261 S1). However, a second subsequent isolate, while still meeting the identity threshold for 262 belonging to the same strain, did not contain the *qacEdelta1* gene and had an MIC of 32 μ g/mL. 263 This observation suggests that the ARG-carrying plasmid can be lost, potentially under reduced 264 selective pressure, and that carrying *qacEdelta1* may associate with CHG resistance in *P*. 265 aeruginosa (Table S1). For S. maltophilia, we observed signs of increased CHG tolerance and 266 intra-species/inter-strain competition during the persistence. In the PT 3 sink drain, the MIC of 267 two intra-strain isolates increased from 16 to 64 μ g/mL between the first and second sampling 268 events. In the PT 8 sink drain, we identified two inter-strain isolates with MICs of 4 µg/mL 269 (S60) and 32 µg/mL (S10) during the first sampling event, and one isolate with an MIC of 64 270 μ g/mL, belonging to the same strain as S10, during the second event. Furthermore, in sink drains 271 of multiple rooms, we detected the same strains of E. miricola (MD 3 and PT 10, PT 2 and 272 PT 7) and S. maltophilia (PT 7 and PT 8) as well as the same species of P. aeruginosa and 273 Delftia tsuruhatensis (Fig. 3b, Fig. S7). Additionally, we found that S. maltophilia and P. 274 *aeruginosa* cohabitated the same sink drain in two patient rooms (PT 5, PT 7). These organisms can be co-colonizers in the respiratory tract of cystic fibrosis patients⁴¹, indicating the possibility 275 276 of contracting both pathogens from the same environmental location⁶¹. It should be noted that 277 these findings are based on a limited number of isolates due to a tradeoff with taxa breadth. 278 Nevertheless, they offer guidance for future studies with larger sample sizes, potentially focusing

- on specific species.
- 280 Of the 37 high-CHG MIC isolates in the cultivation dataset, 19 were sequenced. Among these,
- 281 we found three *S. maltophilia*, two *P. aeruginosa*, seven *E. miricola*, two *Cupriavidus*
- 282 *metallidurans*, and two *D. tsuruhatensis* isolates. The remaining three isolates had ambiguous
- species assignments possibly belonging to *D. tsuruhatensis*, *Delftia acidovorans*, or *S.*
- 284 *maltophilia*. While *S. maltophilia*, *P. aeruginosa*, and *E. miricola* are more often recognized in
- 285 clinical cultures, C. metallidurans, D. tsuruhatensis, and D. acidovorans are gaining attention as
- 286 emerging opportunistic pathogens $^{62-67}$.



287

Fig. 3 Indications of a) bacterial persistence and in situ evolution of opportunistic

289 pathogens in sink drains, as well as b) their potential dissemination across multiple MICU

290 **rooms.** Patient rooms were deidentified. See Fig. S7 for additional species with multiple isolates

291 detected in several MICU rooms during the same sampling event.

292 Molecular mechanisms conferring chlorhexidine resistance are heterogeneous and

293 remain largely undiscovered

294 Across high-CHG-MIC species, antibiotic efflux was the most prevalent and abundant identified

resistance mechanism (Fig. 4a). *P. aeruginosa* harbored a significantly greater quantity and

- 296 variety of ARGs than other species. However, while C. metallidurans harbored fewer ARGs,
- 297 most of its ARGs were mobile (6 out of 8 on average). ARG profiles of high-CHG-MIC species
- 298 demonstrated heterogeneity both within and across species (Fig. 4b-c). We detected several
- ARGs falling into Q1 of the health risk index ranking⁶⁸ in ≥ 2 species (out of 7), including *sme*
- 300 family, *sul1*, and *adeF*. Particularly, *adeF* was present in all high-CHG-MIC isolates except *P*.
- 301 aeruginosa.

- 302 Although many ARGs were identified, only two known to reduce susceptibility to CHG,
- 303 $qacEdelta1^{69-71}$ and $norA^{72-75}$, were observed in 63 sequenced isolates (Table S4). Among the
- 304 high-CHG-MIC isolates, only *qacEdelta1* was detected, and this was limited to four out of 19
- 305 such isolates belonging to two species (*C. metallidurans* and *P. aeruginosa*, Fig. 4b-c). In
- addition, two *Acinetobacter radioresistens* isolates sharing the same ARG profile exhibited \geq 16-
- 307 fold CHG MICs difference (Fig. 5c). These, in combination, indicate that novel ARGs or
- 308 pathways conferring CHG resistance remain to be discovered.

309

- 310
- 311
- 312




Fig. 4 Antibiotic resistance mechanism and gene profiles of the sequenced high-CHG-MIC isolates (MICs \geq 128 µg/mL). a) Distribution of antibiotic resistance mechanisms and genes

313

316 across different species. ARG numbers: Error bars represent the mean standard error. Resistance

- 317 mechanisms: Numbers in the main heatmap represent the average ARG counts for each
- 318 mechanism; those in the marginal heat blocks indicate the number of high-CHG-MIC isolates
- per species. Antibiotic resistance gene profiles of high-CHG-MIC isolates: b) all species except
 Pseudomonas aeruginosa, c *Pseudomonas aeruginosa*. Each square in the dot plots represents
- 320 *T seudomonas deruginosa*, **C***T seudomonas deruginosa*. Each square in the dot plots represent 321 one ARG copy. ARGs were named according to the curated CARD short names (output of
- 322 Resistance Gene Identifier, Methods)⁷⁶. ARGs located within MGEs were classified as MGE-
- 323 carried; those situated within a 5 kb proximity to an MGE were considered MGE-associated;
- both were deemed mobile. Health risk index ranks from Zhang et al. were used to prioritize
- 325 ARGs⁶⁸. Abbreviations: **a**) EF: efflux, IN: inactivation, RP: reduced permeability, TR: target
- 326 replacement, TP: target protection, TA: target alteration; **b**) vanY*: vanY gene in vanM cluster,
- 327 *vanW**: *vanW* gene in *vanG* cluster, *vanT**: *vanT* gene in *vanG* cluster; **c** *vanH**: *vanH* gene in
- 328 vanB cluster, gyrA*: Pseudomonas aeruginosa gyrA conferring resistance to fluoroquinolones,
- 329 emrE*: Pseudomonas aeruginosa emrE, CpxR*: Pseudomonas aeruginosa CpxR, catB7*:
- 330 *Pseudomonas aeruginosa catB7, soxR*: Pseudomonas aeruginosa soxR*; legend) $g_Delftia$:
- ambiguous species *Delftia tsuruhatensis* or *Delftia acidovorans*, g_Delftia or
- 332 g_Stenotrophomonas: ambiguous species Delftia tsuruhatensis, Delftia acidovorans or
- 333 Stenotrophomonas maltophilia.
- 334

335 To further investigate the genetic characteristics of clinically important bacteria regarding CHG

- tolerance, we examined the presence, types, and differential abundances of ARGs and mobile
- 337 ARGs with varied CHG MICs in S. maltophilia, E. miricola, A. radioresistens, and P.
- 338 *aeruginosa* (Fig. 5). Among these species, *P. aeruginosa* was the only one found to carry a
- 339 known CHG-ARG, *gacEdelta1*, which was present in three out of the six isolates. Specifically,
- 340 two isolates had MICs of 128 μ g/mL and one had an MIC of 32 μ g/mL. In all cases, the gene
- 341 was located on a plasmid, indicating potential for horizontal gene transfer. Although no known
- 342 CHG ARG was predicted in the other two species, upon qualitative inspection, we identified
- 343 ARGs potentially associated with CHG tolerance. These included *sul2*, *smeA/B/C/S* for *S*.
- 344 *maltophilia*, and *smeD/E/F/R*, *qacJ*, *AAC(6')-Iap* for *E. miricola*. Future research could
- interrogate these gene candidates, especially the Q1 health risk ARGs⁶⁸ sul2 and smeB/D/E/F/S,
- 346 by employing more quantitative and systematic surveys along with experimental validations. The
- taxon *E. miricola* may be associated with high CHG MICs, as all isolates exhibited MICs of 256
- μ g/mL or higher. Particularly, isolate S36 had an MIC of 512 μ g/mL. Compared to other *E*.
- 349 *miricola* isolates, it contained more types and quantities of ARGs, and more critically two unique
- 350 mobile ARGs (*qacJ* and AAC(6')-*Iap*). *P. aeruginosa* exhibited significantly higher quantities of
- 351 ARGs and mobile ARGs compared to most species in the dataset (Table S4) and consistently
- 352 ranked in the top three for all three indices. Notably, several isolates warrant further attention:
- isolate S30, with an ambiguous species assignment between *Citrobacter amalonaticus* and
- 354 *Citrobacter freundii*; S25, belonging to a novel species of genus *Cupriavidus*; and S13 and S14,
- 355 identified as *Cupriavidus metallidurans*, all contained a high number of ARGs or mobile ARGs.
- 356 However, we could not establish statistical correlations between CHG MICs and the quantities of

ARGs, mobile ARGs, or plasmid-borne ARGs due to the broad scope of the study and the

358 limited number of sequenced isolates.






Fig. 5 ARG profiles of isolates with varying CHG MICs, including ARG mobility and

- health risk index for: a) Stenotrophomonas maltophilia, b) Elizabethkingia miricola, c)
- 362 *Acinetobacter radioresistens*, and d) *Pseudomonas aeruginosa*. Each square in the dot plots 363 represents one ARG copy. ARGs were named according to the curated CARD short names
- 364 (output of Resistance Gene Identifier, Methods)⁷⁶. ARGs located within MGEs were classified as
- 365 MGE-carried; those situated within a 5 kb proximity to an MGE were considered MGE-
- 366 associated; both were deemed mobile. Health risk index ranks from Zhang et al. were used to
- 367 prioritize ARGs⁶⁸. Abbreviations: a) $vanY^*$: vanY in vanM cluster, $vanY^{**}$: vanY in vanA cluster,

368 *vanH*: vanH* in *vanO* cluster; b) *vanW*: vanW* gene in *vanG* cluster, *vanT*: vanT* gene in *vanG*369 cluster.

370 *qacEdelta1*-carrying multidrug-resistant plasmids are a potential concern


- 371 *qacEdelta1* was detected exclusively on plasmids in six isolates (Fig. 6, Table S5). Each isolate
- 372 harbored one *qacEdelta1*-carrying plasmid. All isolates were recovered from sink drains, with
- 373 S30 originating from a staff-only restroom and the remaining coming from patient rooms.
- 374 Notably, all six *qacEdelta1*-carrying plasmid scaffolds had \geq 3 ARGs regardless of species, five
- 375 of which carried the highest number of ARGs among all plasmid scaffolds in the sequenced
- 376 isolates (six ARGs in one plasmid scaffold). Another notable feature shared by these plasmids
- 377 was the colocalization of *qacEdelta1* and *sul1*, arrayed next to each other as a cassette.
- 378 Importantly, *sul1*, a Q1 health risk ARG, confers resistance to sulfonamide antibiotics and its
- 379 proximity to *qacEdelta1* merits attention.

380 The *qacEdelta1*-carrying plasmid scaffolds could be classified into four types according to blastn

alignments⁷⁷, and type-1 and type-3 plasmid scaffolds were possibly associated with high CHG

- tolerance. Type 1 contained two identical plasmid scaffolds in two isolates of the same *P*.
- *aeruginosa* strain (S5, S44). Type 2 comprised a plasmid scaffold from another *P. aeruginosa*
- 384 strain (S37) that was closely related to type 1 with 8 bases unaligned. Type 3 was composed of
- the other two identical plasmid scaffolds in two isolates of the same *C. metallidurans* strain (S13,
- 386 S14). Type 4 held a different plasmid scaffold in an isolate with an ambiguous species
- 387 assignment between Citrobacter amalonaticus and Citrobacter freundii (S30) which shared
- 388 common regions with the other plasmids. It is worth highlighting that the top BLAST hits for
- type-1 plasmid scaffolds (query coverage: 100%, identity \ge 99.99%, database: nr/nt) matched
- 390 two plasmids from clinical *P. aeruginosa* strains one from a bloodstream infection and the
- 391 other from sputum both collected in Chicago (Table S5). While the two type-1 plasmid
- 392 scaffolds shared an identical sequence alignment in the two *P. aeruginosa* strain-matched
- isolates, S5 and S44, they were positioned in opposite directions and were not the most closely
- related phylogenetically (Fig. 6). This suggests that carriage of this ARG cassette is dynamic and
- 395 large-scale genomic changes like inversions might occur. Nevertheless, they still manifest the
- 396 same MIC (128 μ g/mL), indicating that the inversion did not disrupt the function of CHG
- tolerance. Notably, the strain of S5 and S44 probably persisted in sink drains over half a year
- 398 (Fig. 3a). In comparison, plasmid scaffolds of S5 S30 and S44 S37 were more closely related,
- respectively. S44 and S37 were two different strains of *P. aeruginosa*, while S5 and S30
- 400 belonged to different orders. This suggests that the *qacEdelta1*-carrying plasmid could be
- 401 transferred in situ not only between environmental bacteria of the same species but also between
- 402 those that are more evolutionarily distant.

- 403 To the best of our knowledge, this study is the first to report the presence of the *qacEdelta1* gene
- 404 on a plasmid in *C. metallidurans*. *C. metallidurans* was traditionally considered non-pathogenic
- 405 until recent case reports suggested otherwise. In 2005, this bacterium was identified in the
- 406 respiratory secretions of cystic fibrosis patients, though its pathogenic effects were not
- 407 understood at the time⁷⁸. In 2011, a case of invasive nosocomial septicemia caused by C.
- 408 *metallidurans* was reported following surgery⁶². Furthermore, in 2015, four cases of catheter-
- 409 related bacteremia due to this bacterium were documented⁷⁹. The growing clinical importance,
- 410 combined with its detection in MICU patient room environments, high CHG tolerance, and
- 411 carriage of a concerning plasmid, implicate the need for further investigations.
- 412



414 Fig. 6 *qacEdelta1*-carrying multidrug-resistant plasmids are of potential concern,

415 particularly type-1 and type-3 plasmid scaffolds, which are possibly associated with high

416 **CHG tolerance. a)** Colocalization of ARGs on the plasmid scaffolds. **b)** Phylogenetic

417 relationship between the isolates. c) Phylogenetic relationship between the plasmid scaffolds. All

- 418 isolates were recovered from sink drains. S30 was from a staff-only restroom, and the other
- 419 isolates were from patient rooms. See Table S5 for more information. ARGs were named
- 420 according to the curated CARD short names (output of Resistance Gene Identifier, Methods)⁷⁶.
- 421 Health risk index ranks from Zhang et al. were used to prioritize ARGs⁶⁸. MLS: macrolides,
- 422 lincosamides and streptogramins.

423 Discussion

- 424 Although CHG is used primarily on patient skin, it could be transferred to hospital environments.
- 425 Once there, CHG likely persists on indoor surfaces despite surface cleaning and disinfection,
- 426 with its concentration decreasing to sublethal levels for some clinically relevant bacteria, as
- 427 demonstrated by our microcosm experiments. This finding was further corroborated by an in-situ
- 428 field survey, which revealed widespread CHG tolerance in MICU environments. Notably, we
- 429 emphasized sink drains as critical hotspots, corroborating previous findings. Further, based on
- 430 the isolation of CHG-tolerant bacteria from doorsills, we urge more attention to indoor air as
- 431 transport mechanisms for resistant organisms. We observed potential evidence of bacterial
- 432 persistence, increased tolerance, and in-situ evolution of opportunistic pathogens in sink drains,
- 433 as well as dissemination across multiple MICU rooms. *S. maltophilia*, *E. miricola*, and *P.*
- 434 *aeruginosa* were highly represented species in the sequenced subset. Through our broad-scope
- 435 study, we found that the molecular mechanisms conferring chlorhexidine resistance were
- 436 heterogeneous and largely undiscovered. Nevertheless, we identified ARG candidates that
- 437 warrant future investigation, particularly two types of *qacEdelta1*-carrying, plasmid-borne
- 438 multidrug-resistant cassettes. These cassettes are potentially concerning for their role in pathogen
- 439 persistence, the development and dissemination of CHG resistance, and broader antibiotic
- 440 resistance.

441 The ways in which humans interact with their environment, including touch and cleaning, along

- 442 with characteristics like surface material, jointly impact the fate of chemicals applied to humans.
- 443 Subsequently, these factors influence the trajectory of microbial ecology and evolution and in
- 444 return affect our exposome⁸⁰. We identified sink drains and air as environmental hotspots for
- 445 CHG tolerance and opportunistic pathogens. Consistent with previous observations⁸¹⁻⁸³, sink
- 446 drains were confirmed as critical reservoirs. CHG-tolerant and/or opportunistic bacteria hosted in
- 447 sink drains, likely within biofilms, could persist for at least half a year, adaptively evolving and
- 448 increasing their CHG tolerance, and potentially disseminating⁸⁴. We hypothesize that water
- 449 availability plays an important role, driving the in-situ microbial survival and persistence as well
- 450 as antimicrobial adaptation and evolution in the built environment (e.g., sink drains). It may exert

- 451 a stronger impact than other factors such as touch frequency and surface material^{85,86}. Building
- 452 on previous evidence that microbes can be transmitted from sinks to patients⁶¹, our findings
- 453 further emphasize the importance of sinks as possible sources of healthcare-associated infections
- 454 and antimicrobial resistance, supporting the waterless ICU initiative⁸⁷.

Since biomass on doorsills reflects what is circulating in the air⁸⁸⁻⁹⁰, indoor air was identified as 455 456 another hotspot, particularly for its role as a transport mechanism for resistant organisms. Unlike 457 in sink drains, where water potentially supports bacterial metabolism and growth, bacteria in dry environments (e.g., doorsills) are more likely dormant⁸⁰. Thus, we hypothesize that these bacteria 458 459 are transferred to such environments and remain in the same state as when they were on human 460 bodies. For example, bacteria detected on doorsills, including A. radioresistens, S. maltophilia, 461 and *E. hormaechei*, may be carried on air currents and settle there along with biological debris 462 (e.g., skin squames) shed by humans. Previous studies have implicated this phenomenon for S. *aureus*^{91,92}. It is possible that settled bacteria could be re-suspended into the air and potentially 463 infect patients. Although high-touch surfaces yielded fewer CHG-tolerant isolates compared to 464 465 sink drains and air, they still hold value for monitoring due to frequent interactions. Note that the roles of environmental locations are dynamic within this interaction model, shifting as conditions 466 467 and time change. For example, sink drains act as reservoirs when they receive inputs from hands, 468 incoming water, and air, hosting microbes in biofilms. They can become sources of exposure 469 when microbes are re-aerosolized⁶¹, or serve as transport mediums when contaminants flow 470 through them to wastewater treatment plants. Similarly, the two hypotheses are also dynamic and

- 471 condition-dependent.
- 472 Detection of CHG-tolerant, ARG-carrying, and/or opportunistic bacteria in environments does
- 473 not necessarily translate to elevated risk of infection and antibiotic resistance due to several
- 474 challenges and knowledge $gaps^{93,94}$. First, more studies are needed to clarify the relationship
- 475 between carrying ARGs and manifesting resistance phenotypes or increased tolerance. For
- 476 instance, while *qacEdelta1* was a shared ARG in some high-CHG-MIC isolates (Fig. 4b-c), its
- 477 presence was not exclusive to these, as it was also identified in two isolates with relatively low
- 478 MICs (*P. aeruginosa*: 32 μ g/mL, below its epidemiological cut-off value 50 μ g/mL¹²; genus
- 479 *Citrobacter*: $\leq 4 \,\mu g/mL$; Table S4). In contrast, carrying *norA* (the other known CHG ARG) in
- 480 *Staphylococcus epidermidis* appeared to associate with reduced susceptibility²⁵. The *norA*-
- 481 carrying isolate from our cohort showed an MIC of 4 μg/mL. Compared with previous reports⁹⁵,
- this was 4.3 times higher than that observed in 33 blood isolates from 1965-1966, 2.1 times that
- 483 of 290 more recent clinical isolates (post-2002), and comparable to that in four isolates from
- 484 infected joint replacements. Future studies should aim to extend these qualitative phenomena
- 485 observed in a limited sample size to quantitative analyses.

486 In addition to these ARGs previously reported to associate with CHG tolerance, we demonstrated

- 487 from various angles that novel resistance mechanisms await discovery, and identified ARG and
- 488 plasmid candidates (i.e., type-1 and type-3 *qacEdelta1*-carrying multidrug-resistant plasmids).
- 489 Despite the richness of available data resources, we were challenged by the poor representation
- 490 of environmental bacteria in current databases. For example, when searching the BLAST
- 491 database for our *qacEdelta1*-carrying plasmid scaffolds, we found two top hits for *P. aeruginosa*
- 492 with 100% query coverage. However, the maximum query coverage was only 46% for
- 493 *Citrobacter spp.* and 20% for *C. metallidurans*. Expanding these databases and performing *de*
- 494 *novo* gene annotations as complementary approaches would be beneficial in the future. To
- 495 further connect carriage of ARGs to resistance phenotypes, future investigations should
- 496 interrogate these candidates using functional metagenomics⁹⁶, knockouts or cloning, as well as
- 497 assess cross-resistance to medically relevant antibiotics via susceptibility tests (e.g., MIC
- 498 assays).

499 Second, the clinical importance of detecting biocide resistance phenotypes in laboratories (e.g.,

500 using MIC assays) is not sufficiently understood and lacks consensus. The clinical relevance

- 501 includes both disinfection efficacy and the evolution of cross-resistance to antibiotics,
- 502 particularly in opportunistic pathogens. Several terms resistance, tolerance, and reduced
- 503 susceptibility are used ambiguously in the field to describe these phenotypes, but their
- 504 definitions and applications are not well standardized. Moreover, there is ongoing debate over
- 505 whether MIC is the appropriate metric for assessing biocide efficacy⁹⁷. MIC, which was
- 506 originally developed for antibiotics, measures the ability of a compound to inhibit bacterial
- 507 growth over 16-24 hours, whereas biocides are often applied at high concentrations for brief
- 508 periods during skin antisepsis or environmental disinfection. Special cases exist, such as CHG
- 509 bathing, where we seek both immediate antiseptic effects and longer-term benefits from residual
- 510 CHG on the skin for up to 24 hours. To address some of these ambiguities, studies have
- 511 proposed new frameworks⁹⁸ and metrics (e.g., the minimum duration for killing) to complement
- 512 MIC. However, these alternatives lack sufficient benchmarking and evaluation of
- 513 generalizability. As surveillance expands, generalizability becomes increasingly important a
- 514 limitation the current gold standard, MIC, also faces. For example, clinical breakpoints for
- 515 chlorhexidine, as with many other antimicrobials, have not yet been established²⁷. Reaching
- 516 consensus on clinical breakpoints and even epidemiological cut-offs is challenging. For instance,
- 517 we used 18.75 μ g/mL as the cut-off for CHG tolerance, as it was indicated as a threshold CHG
- 518 skin concentration³; however, a recent study has shown disagreement⁹⁹. Nonetheless, CHG
- 519 concentrations used in clinical applications on skin and mucosal surfaces are much higher than
- 520 the highest MICs identified in our environmental isolates.

- 521 Large-scale environmental surveillance introduces additional challenges. During MIC assays,
- 522 despite following the CLSI standards¹⁰⁰ as closely as possible, we could not confirm that all
- 523 inocula were standardized to 10^4 CFU per 5- to 8-mm diameter spot (Methods) because the
- 524 taxonomy and growth characteristics of isolates were unknown at the time of testing.
- 525 Furthermore, it remains unclear whether the standard CFU threshold has the same clinical
- 526 relevance for environmental isolates as it does for clinical isolates, which were used to develop
- 527 the standard. The limitations of MIC extend beyond the lab. In environmental settings, microbes
- 528 rarely exist in isolation or as free-living cells; rather, they often form biofilms within complex
- 529 communities where synergistic/competitive interactions and physical protection may occur. As a
- 530 result, assays that simulate their in-situ states may offer more accurate insights. Alternative
- 531 approaches, such as examining contact times necessary to achieve a reduction threshold⁹⁷ or
- using microcosm experiments, like those employed in our study, may provide better
- 533 approximations of real-world conditions. For instance, we examined bacterial survival following
- 534 24-h CHG exposure on surface coupons (Fig. 1c), which better approximates in-situ conditions
- than liquid media assays. However, this approach requires optimization. To ensure technical
- 536 feasibility, we used a higher starting bacterial density than is typically found on uncontaminated
- 537 hospital surfaces. This version simulates a scenario where residual CHG is present on a surface,
- and a high burden of pathogens is introduced (e.g., through sneezing). More research is needed
- 539 to develop consensus methods that are applicable to real-world scenarios.
- 540 Furthermore, researchers should be more explicit when communicating findings. For example,
- 541 while chlorhexidine digluconate is the most used formula, other forms, such as chlorhexidine
- 542 acetate, exist. We have encountered instances where the type of formula was not explicitly
- 543 reported in the literature, hindering normalized evaluations through reviews and meta-
- 544 analyses¹⁰¹.
- 545 Despite these challenges, we conducted surveillance of CHG tolerance in built-environment
- 546 isolates, a practice less common than in clinical and animal isolates. The MICs of environmental
- 547 isolates are generally considered lower (Table S6)^{16,17,19,22-24,102,103}. However, bacteria isolated in
- 548 our study, especially those from sinks, exhibited CHG MICs at the high end of the reported
- 549 spectrum^{12,15,27,101,104-108}. Although further investigation is needed to determine whether our
- 550 isolates represent a statistically significant increase in tolerance, the results suggest that the
- 551 MICU environment harbors CHG-tolerant microbes, raising a potential warning sign.
- 552 Moving forward, we should further scrutinize the environmental hotspots (e.g., sink drains, air)
- and establish models to quantify the complex human-environment and chemical-microbe
- 554 interplay. First, combining broad-scope studies with more focused, larger-sized studies is
- recommended. We should collect denser longitudinal samples and richer metadata; for example,

- a logical next step would be to survey chlorhexidine concentrations in MICUs. Second, profiling
- these samples using multimodal approaches, such as combining multi-omic sequencing of
- 558 communities with whole-genome sequencing of isolates, could provide deeper insights. Third,
- 559 pairing environmental and human microbiota could uncover more nuanced connections.
- 560 Furthermore, as our understanding in MICUs advances, studies could be expanded to other
- 561 buildings (e.g., entire hospitals, veterinary facilities, homes, athletic facilities) to determine
- 562 whether findings surrounding CHG tolerance are unique to MICUs, hospitals, or built
- 563 environments in general.
- 564 In summary, by combining microcosm experiments with field surveys, we provided a
- 565 comprehensive depiction of CHG tolerance in MICU environments, connecting chemical,
- 566 microbial, and molecular perspectives. Understanding these interactions could reveal potential
- 567 intervention opportunities for infection prevention and lead to actionable recommendations for
- 568 regulations and healthcare policy. Given the critical value of CHG in healthcare and the dearth of
- 569 viable alternatives, proactive measures are important, such as integrating environmental
- 570 management with clinical interventions, expanding stewardship programs, and exploring
- 571 alternatives to CHG. Furthermore, due to chlorhexidine's versatile applications, the insights
- 572 gained from this study could benefit a broader audience, informing stewardship practices in
- 573 veterinary hospitals and other built environments, as well as guiding consumer use of antiseptics
- 574 and disinfectants.

575 Methods

576 Chlorhexidine persistence on surfaces

- 577 We investigated the chlorhexidine persistence on three surface materials commonly found in
- 578 hospital (laminate wood, plastic [high-density polyethylene; HDPE], metal [stainless steel]) in
- 579 response to six different cleaning practices used commonly on inanimate hospital surfaces (no
- 580 cleaning, clean with water, disinfect with ethanol, bleach, peracetic acid, or benzalkonium
- 581 chloride) (Fig. S1).

582 Microcosm setup

- 583 Each surface was cut into 4"×8" coupons, and each coupon was divided into 1"×1" sections by
- drawing markers. The coupons were UV sterilized for 15 minutes before applying 2%
- 585 chlorhexidine digluconate (CHG, IUPAC name: (1E)-2-[6-[[amino-[(E)-[amino-(4-
- 586 chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-
- 587 chloroanilino)methylidene]guanidine;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid)
- 588 solution (w/v, Sigma-Aldrich, St. Louis, MO, USA). The concentration 2% was selected to
- 589 represent commercial CHG wipes used in patient bathing^{109,110}. We first folded a Kimwipe

- 590 (Kimberly-Clark, Irving, TX, USA) in half three times to get a square about 2"×2" and 8 layers
- thick. We then pipetted 1 mL CHG onto the Kimwipe and wiped in a zigzag pattern along the
- 592 long axis of the surface, such that the whole surface was covered after 5 passes. Wiping was
- 593 repeated with a second Kimwipe from the opposite direction. Once the surface dried, an initial
- 594 CHG measurement was taken in biological triplicate, representing 0 min. Each 1"×1" section
- 595 was swabbed using a nonsterile cotton swab (Puritan, Guilford, ME, USA) premoistened in 0.8
- 596 mL deionized water. The swabbing was conducted with consistent pressure and speed in two
- 597 directions (up and down, left and right) for 15 s total. The swab was then stored in the deionized
- 598 water for extraction and CHG concentration measurement.
- 599 Simulated cleaning practices were applied to CHG-treated surfaces using the same wiping
- 600 technique. A group of surfaces that were not wiped served as baseline controls. The wiping
- 601 solutions included deionized water, 70% ethanol (Decon Laboratories, King of Prussia, PA,
- 602 USA), 10% bleach (Clorox, Oakland, CA, USA), 0.2% peracetic acid (Sigma-Aldrich, St. Louis,
- MO, USA), and 0.26% benzalkonium chloride (MP Biomedicals, Santa Ana, CA, USA; C8-
- 604 18)¹¹¹. The CHG concentrations were measured in biological triplicate at 5 additional timepoints
- 605 (10 min, 1 h, 3 h, 6 h, and 24 h) following the same method. We selected 24 h as an experimental
- 606 cycle because in MICU, patients were bathed with CHG wipes on a daily basis. The coupons
- 607 were kept in light-proof compartments when not being wiped or swabbed. This was repeated for
- 608 each disinfectant and each surface for 8 trials, yielding 24 biological replicates in total.

609 Swab extraction and CHG concentration measurement

- 610 CHG on swabs was extracted into water following an adaptation of CDC's Swab Extraction
- 611 Method^{94,112,113}. The Falcon tube was vortexed at maximum speed for 1 min and shaken at 180
- 612 rpm and 25 °C for 10 min, followed by careful squeezing against the tube wall and removal of
- 613 the swab. CHG concentration was determined by a previously reported colorimetric assay with
- 614 modifications^{3,114,115}. We mixed 500 μ L CHG solution with 500 μ L
- 615 hexadecyltrimethylammonium bromide (0.01 g/mL in deionized water, Sigma-Aldrich, St.
- 616 Louis, MO, USA) and 200 μL sodium hypobromite (Aqua Solutions, Deer Park, TX, USA).
- 617 Absorbance of the mixture was measured at 262 nm using a spectrophotometer (UV-2450,
- 618 Shimadzu, Kyoto, Japan).

619 Quantification of CHG recovery rates from surfaces and application efficiency to surfaces

- 620 We examined the CHG recovery rates from different surface materials using the same swabbing
- 621 technique and accounted for these rates in calculating the CHG concentration on surfaces (Table
- 622 S7). After UV sterilization, we pipetted 100 μ L 2% CHG onto a 1"×1" square for a total of 10
- 623 replicates each surface type. Additionally, 100 μL 2% CHG was directly pipetted onto a swab to
- 624 investigate the recovery rate of the swab extraction. When we directly applied CHG onto swabs,

625 85.46% was recovered in the measurement. For the tested surfaces, metal had a comparably high

- recovery rate (83.04%), indicating that almost all the CHG (97.16%) on a metal surface can be
- 627 collected by swabbing. In contrast, plastic and laminate wood both retained CHG in sampling,
- 628 with recovery rates of 69.79% and 55.58%, respectively.
- 629 CHG transfer rates from the Kimwipe to the surfaces in application was quantified afterwards
- 630 (Table S8). Upon wiping a surface with a CHG wipe, we found that only 4-7% CHG on the wipe
- 631 was transferred onto the surfaces. In comparison to the recovery rates from surfaces by swab
- 632 sampling, the transfer rates showed an opposite trend across surface materials. While metal had
- 633 the highest recovery rate in sampling, it captured the least CHG in application. Furthermore, the
- 634 values were within the range of disinfectants released from ready-to-use Towelettes¹¹⁶, validating
- 635 that our application technique mimics the usage of commercial disinfectants.

636 Viability assay of bacterial isolates on CHG-contaminated surfaces

- 637 We tested the survival of bacterial isolates on plastic surfaces after exposure to various
- 638 concentrations of CHG for 24 h in biological triplicate. Four bacterial isolates (*Escherichia coli*
- 639 [ATCC 25922], *Klebsiella pneumoniae* [ATCC 13883], *Klebsiella variicola* [20-20012]³⁷, and
- 640 *Staphylococcus aureus* [ATCC 29213]) were selected as model strains. Plastic was selected as a
- 641 representative surface because it is a common material of equipment in the immediate vicinity of
- 642 patients and healthcare workers (e.g., bedrail, nurse call button, keyboard, mouse). Five different
- 643 CHG concentrations (31.00, 15.50, 3.10, 0.31, 0 [positive control] µg/cm²) were tested to cover
- 644 the range of CHG persisting on surfaces under disinfection and cleaning.
- 645 To prepare bacterial inocula, the second passage of the stock culture were grown at 37°C to the
- 646 late exponential phase and harvested at 3000 rpm for 1 min. The pellet was then resuspended in
- 647 phosphate-buffered saline (PBS). The bacterial cell density in the inocula was determined by
- 648 spread plating. To prepare surface coupons, HDPE plastic was cut into 2"×2" squares, UV
- sterilized for 15 min, and placed in a petri dish. CHG was applied to the center $1^{"}\times1^{"}$ of the
- 650 coupon by pipetting 100 μ L solution and spreading evenly with the pipette tip. Subsequently,
- $100 \,\mu\text{L}$ isolate suspension was applied using the same technique¹¹⁷. An additional coupon
- 652 inoculated with 100 μL PBS was included as the negative control. Surfaces were kept in dark at
- 653 room temperature.
- After 24 h, bacteria were sampled from surfaces and the surviving numbers were counted. Each
- surface was first dry swabbed for 5 s and wet swabbed twice for 7.5 s each time after rinsing in 1
- 656 mL PBS. Finally, the swab was squeezed against the tube wall to expel any residual liquid¹¹⁷.
- 657 Samples were diluted and 100 μL of each dilution was spread plated onto TSA plates. The plates
- 658 were incubated at 37°C for 24 hours to count the colonies.

659 Field survey in a Medical Intensive Care Unit

660 Sample collection

- 661 We collected 219 swab samples from seven different locations (e.g., bedrails, nurse call buttons,
- doorsills, keyboards, light switches, proximal sink drains; Table S3) in the MICU at Rush
- 663 University Medical Center over two sampling events (February and July, 2018) (Fig. S2),
- 664 including negative field controls and negative media controls. The MICU was selected because
- 665 intensive care units are known to have high prevalence of antibiotic-resistant organism
- 666 colonization and infection, and because patients in the MICU received daily skin cleansing with
- 667 2% CHG-impregnated cloths (Sage 2% Chlorhexidine Gluconate Cloths, Stryker, Portage, MI,
- 668 USA)^{118,119}, which gives this environment a higher probability but also a lower threshold for
- 669 acceptable risk of containing antibiotic-resistant and CHG-tolerant organisms. Sampling
- 670 locations were selected to capture a variety of surfaces reflecting different ways in which people
- 671 interact with the surface¹²⁰ and time-integrated aggregates of what was in the air (i.e.,
- doorsills)¹²¹. Sites were further selected to facilitate comparison with other hospital surveillance
- 673 studies¹²² and to keep a relatively balanced number of samples from each touch frequency group.
- 674 Touch frequency categorization included bedrails and nurse call buttons as high-touch,
- 675 keyboards as medium-touch, light switches as low-touch surfaces, and doorsills as no-touch.
- 676 Sink drains were labeled as themselves. Touch frequency designations were based on interviews
- 677 with healthcare professionals and prior evidence from the literature 123-126.
- 678 Swabbing was conducted following CDC's Environmental Surface Sampling Swab Contact
- 679 Method. Briefly, we used three sterile Nylon Flocked Dry Swabs (COPAN Diagnostics,
- 680 Murrieta, CA, USA) premoistened with PBS to increase the recovery of biomass. Surfaces were
- 681 swabbed in their entirety three times with consistent pressure and speed. Each time, we rotated
- the swabs and switched their order. Swabs were stored in 15 mL tubes with PBS and transferred
- to the lab on ice within 24 hours for immediate processing. Temperature, relative humidity,
- 684 isolation level, and patient mobility for each patient room were recorded. The surface area of
- 685 each sampling location was measured (Table S3).

686 Swab extraction, sample cultivation, and initial screening

- 687 Biomass on swabs was extracted into PBS following an adaptation of CDC's Swab Extraction
- 688 Method^{94,112,113}. Briefly, the Falcon tubes with swabs inside were vortexed at maximum speed
- for 10 s, shaken at 180 rpm and 25 °C for 10 min, and then vortexed again for 10 s, followed by
- 690 careful squeezing against the side of the tube and removal of the swabs.
- 691 The samples were then subjected to cultivation and screening following a protocol modified
- from a previous study¹²⁷ (Fig. S3). Inocula were diluted to obtain between 30 and 300 colonies
- 693 per plate. 100 μL of inoculum was spread plated on tryptic soy agar supplemented with 4 mg/L

- 694 itraconazole (TSAI) and incubated at 25°C for 4 days. When observable growth was detected,
- 695 morphologies of colonies were characterized using standardized ontologies for streamlined
- analysis, and a representative number of colonies belonging to each morphology type were
- 697 picked and stored in glycerol at -80°C. These plates were then replica plated onto blood agar and
- 698 chlorhexidine agar plates for initial screening¹²⁸. Chlorhexidine agar plates contained 10.56
- 699 μg/mL chlorhexidine (equivalent to 18.75 μg/mL chlorhexidine digluconate, Sigma-Aldrich, St.
- 700 Louis, MO, USA). Staphylococcus aureus ATCC 25923, Staphylococcus epidermidis ATCC
- 701 12228, and *Pseudomonas putida* 56A10 (in-house ID)¹²⁹ were used as control strains in this
- 702 chlorhexidine screening process. The chlorhexidine concentration was selected for initial
- tolerance screening because it was reported as the minimum effective concentration associated
- with significantly decreased colony counts of Gram-positive bacteria on the skin of patients who
- 705 were bathed daily with CHG in the MICU. In addition, all the patient skin isolates recovered in
- 706 the study had MICs below 18.75 μ g/mL CHG³.

707 Antimicrobial susceptibility testing

- We confirmed and refined chlorhexidine tolerance observed in the initial screen using a simplified
 agar dilution method adapted from the CLSI standard M07Ed11¹⁰⁰. Briefly, agar dilution plates
- with different concentrations of CHG $(0, 4, 8, 16, 32, 64, 128, 256, 512 \mu g/mL)$ were made with
- 711 Mueller-Hinton Agar (MHA; Sigma-Aldrich, St. Louis, MO, USA) and chlorhexidine digluconate
- solution (20% w/v, Sigma-Aldrich, St. Louis, MO, USA). Each isolate was first inoculated from
- frozen stock in 100 µL TSB in a sterile 96-well clear round-bottom not-treated microplate (Corning,
- 714 NY, USA) and incubated at 37 °C for 24 h, yielding F1. F1 was subcultured in 100 μL TSB with
- a 96-pin microplate replicator (transfers 1 µL inoculum each pin, Boekel Scientific, Feasterville-
- 716 Trevose, PA, USA) and incubated for another 24 h, yielding F2. F2 was inoculated onto surfaces
- of the agar dilution plates in biological triplicate with the 96-pin replicator, starting from the lowest
- 718 concentration to the highest. MICs were determined after incubating the plates at 37 °C for 20 h.
- 719 Negative controls and two quality control (QC) strains were included in every batch. The two QC
- strains were both MRSA with CHG MICs 1-2 and 8 μ g/mL, respectively³⁷.

721 Genomic exploration of isolates recovered in the MICU

722 Whole-genome sequencing

- A subset of 63 isolates were selected for whole-genome sequencing in two batches. Three
- negative controls were processed in parallel to samples throughout the entire pipeline, and all
- isolates were sequenced at 2×150 bp. The first batch was conducted by the Broad Institute using
- a fluorescent dye-based method on an Illumina HiSeq platform as previously described¹²⁹. The
- second batch was performed at the NUSeq Core Facility at Northwestern University on an
- 728 Illumina NovaSeq 6000 platform using an SP flow cell, and the sequencing library was prepared

- using the Illumina Nextera XT DNA Sample Preparation Kit following the kit protocol. The
- average coverage depth was $214.9 \times (87.5 \times -536.5 \times)$ by estimation assuming 5 Mb for bacterial
- 731 genome sizes.

732 Genome assembly, taxonomic identification, and phylogenetic analysis

- The analysis pipeline was illustrated in Fig. S8. Raw reads were first quality checked by
- FastQC¹³⁰ (v0.11.5) and cleaned by fastp¹³¹ (v0.23.2). Genomes were assembled using
- 735 SPAdes¹³² (v3.15.0) with the assembly quality assessed by Check M^{133} (v1.2.2) and QUAST¹³⁴
- 736 (v5.2.0). In the genome assembly, SPAdes parameters --careful and --isolate were compared and
- selected according to the quality of the resulted scaffolds. Integrating insights from the research
- community¹³⁵, --careful was used for all samples except isolate S33. We then performed
- taxonomic assignments using KmerFinder¹³⁶⁻¹³⁸ (v3.0.2) with the database version 20211017 and
- 740 PhyloPhlAn¹³⁹ (v3.0.36) metagenomic SGBs with the database SGB.Jul20. Isolates with
- inconsistent assignments were further examined using autoMLST¹⁴⁰ de novo mode and MiGA
- 742 TypeMat¹⁴¹. Phylogenetic trees among bacteria isolates were constructed with PhyloPhlAn
- 743 (v3.0.36) on the low diversity setting using the assembled scaffolds. The strain-level relationship
- between isolates was determined using fastANI for ANI values $\geq 99.99\%^{59,60}$. The phylogenetic
- tree among plasmid scaffolds (Fig. 6c) was constructed with Clustal Omega¹⁴².

746 Analysis of antimicrobial resistance genes

- 747 ARGs were predicted using Resistance Gene Identifier (RGI, v6.0.2) coupled with the
- 748 Comprehensive Antibiotic Resistance Database (CARD, v3.2.7)⁷⁶. Only ARGs under perfect and
- strict paradigms were included in the downstream analyses. ARGs presented in this study were
- named according to the curated CARD short names (i.e., Best Hit ARO output by RGI)⁷⁶.
- 751 Briefly, if the original gene name is less than 15 characters, the CARD short name is identical;
- otherwise, it has been abbreviated by CARD curators specifically to identify the proper gene or
- 753 protein name. Mapping between a unique CARD short name and the corresponding metadata can
- be found in the CARD ontology database (https://card.mcmaster.ca/), including AMR gene
- families, drug classes, resistance mechanisms, resistomes, and homolog sequences. Mobile
- 756 genetic elements were predicted using geNomad¹⁴³ (v1.5.2), MobileElementFinder¹⁴⁴
- 757 (mge_finder v1.1.2, mgedb v1.1.1, blastn v2.14.0+), and VRprofile2¹⁴⁵ with default parameters.
- 758 In MobileElementFinder outputs, putative composite transposons were excluded to avoid false-
- positive predictions. To infer the mobility of ARGs, they were classified as MGE-carried, MGE-
- associated, or MGE-unassociated according to their relative location to MGEs. Specifically,
- ARGs located within MGEs were classified as MGE-carried, whereas those situated within a 5
- 762 kb proximity to an MGE were considered MGE-associated. Both MGE-carried and MGE-
- associated ARGs were deemed mobile^{68,146}. To prioritize ARGs, health risk indices from Zhang
- real. were employed, which they crafted by integrating factors of human accessibility, mobility,

- pathogenicity and clinical availability⁶⁸. To contextualize our findings within the framework of
- 766 known CHG resistance mechanisms, we carried out a targeted review and curated a list of CHG
- 767 ARGs, annotating each with a confidence level based on whether the evidence was correlational
- or causal (Table S9).

769 Statistical analysis

- 770 Statistical analyses and data visualization were conducted in R (v4.0.4)¹⁴⁷ with packages such as
- dplyr¹⁴⁸, stringr¹⁴⁹, rstatix¹⁵⁰, ggplot2¹⁵¹, ComplexHeatmap¹⁵², and gggenes¹⁵³. Differences
- between groups were determined by Student's *T*-test with p-values adjusted by the Benjamini-
- Hochberg method or ANOVA coupled with Tukey's post hoc test. $p \le 0.05$ was defined as
- statistically significant. Significance codes are as follows: p > 0.05 (ns), 0.01 (*),
- 775 $0.001 (**), <math>0.0001 (***), and <math>p \le 0.0001$ (****).

776 Availability of data and materials

- 777 The raw whole genome sequencing data of bacteria isolates are available in the NCBI SRA
- repository under BioProject number PRJNA1169385. The data will be accessible upon
- 779 manuscript acceptance. Source code for the analyses are available under MIT license at
- 780 <u>https://github.com/hartmann-lab/Chlorhexidine_Tolerance_Hospital_Environments</u>. Bacteria
- 781 isolates are available upon request (erica.hartmann@northwestern.edu).

782 Supplementary figures

- 783 Fig. S1 Coupons used in the microcosm experiments examining chlorhexidine persistence.
- 784 Grids on the coupons indicate specific swabbing sites.
- 785 Fig. S2 a) Floor plan of the Medical Intensive Care Unit at the sampled hospital. b)
- 786 Illustrations of the swabbed area for the sampled environmental locations.
- 787 Fig. S3 Cultivation and screening pipeline. TSAI is tryptic soy agar (TSA) supplemented with
- 4 mg/L itraconazole. TSA+CHX is TSA containing 10.56 μg/mL chlorhexidine powder
- 789 (equivalent to 18.75 μ g/mL CHG).

790 Fig. S4 Absolute bioburden of bacteria (log₁₀CFU) in the entirety of the dry surfaces and by

- 791 **swabbing the proximal sink drain.** The bacteria CFUs were not normalized by sampling area.
- 792 Differences between groups were determined by unpaired *t*-tests with the Benjamini-Hochberg
- adjustment. To avoid mis-interpreting data with small colony counts, we empirically set the limit
- of quantification (LOQ) of our culture efforts as colony counts = 3. Values below this threshold
- 795 were recorded as half of LOQ (i.e., 1.5). Nurse call button is abbreviated as nurse call in the
- 796 figure.

- 797 Fig. S5 No significant differences were observed in: a) Unit area bioburden of bacteria
- between the two sampling seasons, **b**) Unit area bioburden of bacteria between patient rooms
- 799 with contact isolation and those without, and c) Proportions of CHG-tolerant bacteria (tolerating
- 800 18.75 µg/mL CHG at 25°C) between contact isolation levels of patient rooms. Cultivation
- 801 temperature was 25°C for all cases. Nurse call button is abbreviated as nurse call in the figure.
- 802 Fig. S6 A phylogenetic tree of all sequenced isolates.
- 803 Fig. S7 Potential dissemination of opportunistic pathogens across multiple MICU rooms.
- Patient rooms were deidentified. Each panel shows one species with multiple isolates detected in
 sink drains of different MICU rooms during the same sampling event.
- 806 Fig. S8 Analysis pipeline of whole-genome sequences.

807 Supplementary tables

- 808 Table S1 Epidemiological cut-off values for CHG resistance.
- 809 Table S2 Statistical testing results of CHG persistence on surfaces. List of abbreviations for
- 810 cleaning: C="No liquid", W= "Water", Q= "Benzalkonium chloride", P= "Peracetic acid", B=
- 811 "Bleach", E= "Ethanol"
- 812 **Table S3 Sample collection metadata. a)** Specific sampling locations within the MICU **b**)
- 813 Distribution of Number of collected samples for each sampling event **c**) List of Abbreviations for
- 814 sampling locations and space types **d**) Surface area of sampling locations
- 815 Table S4 Antibiotic resistance genes (ARGs, curated CARD short name) predicted using
- 816 **Resistance Gene Identifier (RGI) and Comprehensive Antibiotic Resistance Database**
- 817 (CARD) under Perfect and Strict paradigms, with further annotations of ARG health risk
- 818 (blue), chlorhexidine MICs (green), taxonomic assignments (orange), sample collection and
- 819 cultivation results (purple), mobile ARGs (gray). List of abbreviations for Space Type: MD =
- 820 "Medication room", PT = "Patient room", CM = "Communicating space", ST = "Staff-only
- 821 restroom." Room numbers were deidentified by randomly generating unique numbers.

822 Table S5 Additional information of *qacEdelta1*-carrying multidrug-resistant plasmid

- 823 scaffolds. a) Metadata of *qacEdelta1*-carrying plasmid scaffolds. b) Intra-species similarity of
- 824 *qacEdelta1*-carrying plasmid scaffolds determined by blastn. c) Inter-species similarity of
- 825 *qacEdelta1*-carrying plasmid scaffolds determined by blastn. **d)** Assessment of the completeness
- 826 of plasmid scaffolds. e) The top BLAST hits for type-1 plasmid scaffolds matched two plasmids

- 827 from clinical *P. aeruginosa* strains one from a bloodstream infection and the other from sputum
- 828 both collected in Chicago.
- 829 Table S6 Reports of the highest CHG MICs (µg/mL) for environmental isolates. Bacteria
- isolated in our study, especially those from sinks, exhibited MICs at the high end of this
- 831 spectrum.
- 832 Table S7 Recovery rate of CHG on different surface materials. The recovery rate measured
- 833 for surfaces was the integrative rate, representing the overall impacts of swabbing on surfaces,
- 834 extracting CHG from the swab, and all the loss in the process.
- Table S8 Transfer rate of chlorhexidine digluconate (CHG) from Kimwipe to surfaces by
 wiping.
- 837 Table S9 A targeted review of antibiotic resistance genes (ARGs) conferring resistance to
- 838 chlorhexidine. CHX resistance: Y, confer resistance to CHX; N, do not confer resistance; C,
- 839 controversial with conflicting results. Correlation & causality: Y, evidence available; N,
- 840 evidence not available; NA, not applicable.

841 Acknowledgements

- 842 This study was partially supported by the Searle Leadership Fund and the Northwestern
- 843 University 2020 NUSeq Pilot Project Program. Additionally, the computational resources and
- staff contributions provided by the Quest high performance computing facility at Northwestern
- 845 University, which is jointly supported by the Office of the Provost, the Office for Research, and
- 846 Northwestern University Information Technology, were instrumental.
- 847 JS was supported by Northwestern University Terminal Year Fellowship from the Richter
- 848 Memorial Fund. Undergraduate researchers received support from Northwestern University
- 849 Undergraduate Research Grants: AW from the Buffett Institute, MK from the Weinberg College
- 850 of Arts and Sciences Summer Undergraduate Research Grant, and YW and YS from the Office
- 851 of Undergraduate Research Summer Undergraduate Research Grant.
- 852 We are deeply thankful to Teppei Shimasaki, Khaled Aboushaala, Thelma Dangana, Yoona
- 853 Rhee and Alexander G. McFarland for their help in sample collection and coordination. Our
- appreciation extends to the clinical staff of the Medical Intensive Care Unit at Rush University
- 855 Medical Center. We gratefully acknowledge Adam J. Glawe and James Lindsay for their
- 856 contributions to microbial cultivation. Finally, we would like to thank the anonymous reviewers
- 857 whose insights significantly improved this manuscript.

858 Reference

- Knox, C. *et al.* DrugBank 6.0: the DrugBank Knowledgebase for 2024. *Nucleic Acids Res* 52, D1265-D1275, doi:10.1093/nar/gkad976 (2024).
- 861 2 Malakova, I. H. T. Effect on Skin Microflora in Hygienic Bathing of Patients with
 862 Chlorhexidine Gluconate Disinfectant and Non-Rinse Product. *Health Sci J.*,
- doi:10.36648/1791-809X.14.2.708 (2020).
- Popovich, K. J. *et al.* Relationship between chlorhexidine gluconate skin concentration
 and microbial density on the skin of critically ill patients bathed daily with chlorhexidine
 gluconate. *Infect Control Hosp Epidemiol* 33, 889-896, doi:10.1086/667371 (2012).
- Rupp, M. E. *et al.* Effect of hospital-wide chlorhexidine patient bathing on healthcareassociated infections. *Infect Control Hosp Epidemiol* 33, 1094-1100, doi:10.1086/668024
 (2012).
- Fruh, R. *et al.* Antibiotic Resistance of Selected Bacteria after Treatment of the
 Supragingival Biofilm with Subinhibitory Chlorhexidine Concentrations. *Antibiotics*(*Basel*) 11, doi:10.3390/antibiotics11101420 (2022).
- Bhardwaj, P., Hans, A., Ruikar, K., Guan, Z. & Palmer, K. L. Reduced Chlorhexidine
 and Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium after
 Serial Chlorhexidine Exposure. *Antimicrob Agents Chemother* 62,
 doi:10.1128/AAC.01235-17 (2018).
- 877 7 Baseri, N., Najar-Peerayeh, S., Bakhshi, B. & Campanile, F. Phenotypic and genotypic
 878 changes of Staphylococcus aureus in the presence of the inappropriate concentration of
 879 chlorhexidine gluconate. *BMC Microbiol* 22, 100, doi:10.1186/s12866-022-02522-0
 880 (2022).
- 881 8 Laumen, J. G. E. *et al.* Sub-Inhibitory Concentrations of Chlorhexidine Induce Resistance
 882 to Chlorhexidine and Decrease Antibiotic Susceptibility in Neisseria gonorrhoeae. *Front*883 *Microbiol* 12, 776909, doi:10.3389/fmicb.2021.776909 (2021).
- Bas, R., Sarkar, S. & Bhattacharjee, C. Photocatalytic degradation of chlorhexidine—A
 chemical assessment and prediction of optimal condition by response surface
 methodology. *Journal of Water Process Engineering* 2, 79-86,
 doi:https://doi.org/10.1016/j.jwpe.2014.05.005 (2014).
- 888 10 Sarkar, S., Bhattacharjee, C. & Curcio, S. Studies on adsorption, reaction mechanisms
 889 and kinetics for photocatalytic degradation of CHD, a pharmaceutical waste. *Ecotoxicol*890 *Environ Saf* 121, 154-163, doi:10.1016/j.ecoenv.2015.04.036 (2015).
- In Zong, Z. & Kirsch, L. E. Studies on the Instability of Chlorhexidine, Part I: Kinetics and
 Mechanisms. *Journal of Pharmaceutical Sciences* 101, 2417-2427,
 doi:https://doi.org/10.1002/jps.23151 (2012).
- Kampf, G. Acquired resistance to chlorhexidine is it time to establish an 'antiseptic
 stewardship' initiative? *J Hosp Infect* 94, 213-227, doi:10.1016/j.jhin.2016.08.018 (2016).
- Babiker, A., Lutgring, J. D., Fridkin, S. & Hayden, M. K. Assessing the Potential for
 Unintended Microbial Consequences of Routine Chlorhexidine Bathing for Prevention of
 Healthcare-associated Infections. *Clin Infect Dis* 72, 891-898, doi:10.1093/cid/ciaa1103
 (2021).
- Van den Poel, B., Saegeman, V. & Schuermans, A. Increasing usage of chlorhexidine in health care settings: blessing or curse? A narrative review of the risk of chlorhexidine resistance and the implications for infection prevention and control. *Eur J Clin Microbiol Infect Dis* 41, 349-362, doi:10.1007/s10096-022-04403-w (2022).

904 15 Kõljalg, S., Naaber, P. & Mikelsaar, M. Antibiotic resistance as an indicator of bacterial 905 chlorhexidine susceptibility. Journal of Hospital Infection 51, 106-113, 906 doi:10.1053/jhin.2002.1204 (2002). 907 16 Keck, N. et al. Long-lasting nosocomial persistence of chlorhexidine-resistant Serratia 908 marcescens in a veterinary hospital. Vet Microbiol 245, 108686, 909 doi:10.1016/j.vetmic.2020.108686 (2020). 910 17 Vigeant, P. et al. An outbreak of Serratia marcescens infections related to contaminated 911 chlorhexidine. Infect Control Hosp Epidemiol 19, 791-794, doi:10.1086/647728 (1998). 912 Okuda, T., Endo, N., Osada, Y. & Zen-Yoji, H. Outbreak of nosocomial urinary tract 18 913 infections caused by Serratia marcescens. Journal of Clinical Microbiology 20, 691-695, 914 doi:10.1128/jcm.20.4.691-695.1984 (1984). 915 19 Allen, J. L., Doidge, N. P., Bushell, R. N., Browning, G. F. & Marenda, M. S. 916 Healthcare-associated infections caused by chlorhexidine-tolerant Serratia marcescens 917 carrying a promiscuous IncHI2 multi-drug resistance plasmid in a veterinary hospital. 918 PLOS ONE 17, e0264848, doi:10.1371/journal.pone.0264848 (2022). 919 20 Carey, D. E. & McNamara, P. J. The impact of triclosan on the spread of antibiotic 920 resistance in the environment. Front Microbiol 5, 780, doi:10.3389/fmicb.2014.00780 921 (2014). 922 Jutkina, J., Marathe, N. P., Flach, C. F. & Larsson, D. G. J. Antibiotics and common 21 923 antibacterial biocides stimulate horizontal transfer of resistance at low concentrations. Sci 924 Total Environ 616-617, 172-178, doi:10.1016/j.scitotenv.2017.10.312 (2018). 925 22 Vásquez-Giraldo, D. F., Libreros-Zúñiga, G. A. & Crespo-Ortiz, M. d. P. Effects of 926 biocide exposure on P. Aeruginosa, E. coli and A. Baumannii complex isolates from 927 hospital and household environments. Infectio 21, 243-250 (2017). 928 23 Braga, T. M., Pomba, C. & Lopes, M. F. S. High-level vancomycin resistant 929 Enterococcus faecium related to humans and pigs found in dust from pig breeding 930 facilities. Vet. Microbiol. 161, 344-349, doi:https://doi.org/10.1016/j.vetmic.2012.07.034 931 (2013). 932 24 Namaki Kheljan, M., Teymorpour, R., Peeri Doghaheh, H. & Arzanlou, M. 933 Antimicrobial Biocides Susceptibility and Tolerance-Associated Genes in Enterococcus 934 faecalis and Enterococcus faecium Isolates Collected from Human and Environmental 935 Sources. Current Microbiology 79, 170, doi:10.1007/s00284-022-02858-w (2022). 936 Horner, C., Mawer, D. & Wilcox, M. Reduced susceptibility to chlorhexidine in 25 937 staphylococci: is it increasing and does it matter? J Antimicrob Chemother 67, 2547-938 2559, doi:10.1093/jac/dks284 (2012). 939 Morrissey, I. et al. Evaluation of Epidemiological Cut-Off Values Indicates that Biocide 26 Resistant Subpopulations Are Uncommon in Natural Isolates of Clinically-Relevant 940 941 Microorganisms. PLOS ONE 9, e86669, doi:10.1371/journal.pone.0086669 (2014). 942 27 Denkel, L. A. et al. Chlorhexidine and octenidine susceptibility of bacterial isolates from 943 clinical samples in a three-armed cluster randomised decolonisation trial. PLoS One 17, 944 e0278569, doi:10.1371/journal.pone.0278569 (2022). 945 Tran, G. et al. Evidence of incompatibility for topical anionic agents used in conjunction 28 946 with chlorhexidine gluconate: A systematic review. Journal of Surgical Dermatology 947 (2016).

- Kaiser, N., Klein, D., Karanja, P., Greten, Z. & Newman, J. Inactivation of chlorhexidine
 gluconate on skin by incompatible alcohol hand sanitizing gels. *Am J Infect Control* 37,
 569-573, doi:10.1016/j.ajic.2008.12.008 (2009).
- 30 Zong, Z. & Kirsch, L. E. Studies on the instability of chlorhexidine, part I: kinetics and
 mechanisms. *J Pharm Sci* 101, 2417-2427, doi:10.1002/jps.23151 (2012).
- 953 31 Abu-Obaid, E. *et al.* Comparative Evaluation of the Antimicrobial Effects of Different
- 954
 Mouthrinses against Streptococcus Mutans: An in Vitro Study. J Clin Pediatr Dent 43,

 955
 398-407, doi:10.17796/1053-4625-43.6.7 (2019).
- Schoi, J. S. [Evaluation of a waterless, scrubless chlorhexidine gluconate/ethanol surgical
 scrub and povidone-iodine for antimicrobial efficacy]. *Taehan Kanho Hakhoe Chi* 38,
 39-44, doi:10.4040/jkan.2008.38.1.39 (2008).
- 959 33 Pons, J. L., Bonnaveiro, N., Chevalier, J. & Crémieux, A. Evaluation of antimicrobial
 960 interactions between chlorhexidine, quaternary ammonium compounds, preservatives and
 961 excipients. *J Appl Bacteriol* 73, 395-400, doi:10.1111/j.1365-2672.1992.tb04994.x
 962 (1992).
- Gkatzonis, A. M. *et al.* A randomized controlled clinical trial on the effectiveness of three
 different mouthrinses (chlorhexidine with or without alcohol and C31G), adjunct to
 periodontal surgery, in early wound healing. *Clin Oral Investig* 22, 2581-2591,
 doi:10.1007/s00784-018-2357-6 (2018).
- Marty Cooney, R. *et al.* The use of 3.15% chlorhexidine gluconate/70% alcohol hub
 disinfection to prevent central line-associated bloodstream infections in dialysis patients. *Br J Nurs* 29, S24-s26, doi:10.12968/bjon.2020.29.2.S24 (2020).
- 970 36 Purdy, K. R. Aspects of chlorhexidine degradation Ph.D. thesis, University of Bath, (1987).
- 37 Lutgring, J. D. *et al.* Development of a Broth Microdilution Method To Characterize
 37 Chlorhexidine MICs among Bacteria Collected from 2005 to 2019 at Three U.S. Sites.
 37 *Microbiol Spectr* 11, e0413422, doi:10.1128/spectrum.04134-22 (2023).
- Htun, H. L., Hon, P. Y., Holden, M. T. G., Ang, B. & Chow, A. Chlorhexidine and
 octenidine use, carriage of qac genes, and reduced antiseptic susceptibility in methicillinresistant Staphylococcus aureus isolates from a healthcare network. *Clin Microbiol Infect*25, 1154 e1151-1154 e1157, doi:10.1016/j.cmi.2018.12.036 (2019).
- Adams, C. E., Smith, J., Watson, V., Robertson, C. & Dancer, S. J. Examining the
 association between surface bioburden and frequently touched sites in intensive care. J *Hosp Infect* 95, 76-80, doi:10.1016/j.jhin.2016.11.002 (2017).
- 982 40
 983 Sum, R., Swaminathan, M., Rastogi, S. K., Piloto, O. & Cheong, I. Beta-Hemolytic
 983 Bacteria Selectively Trigger Liposome Lysis, Enabling Rapid and Accurate Pathogen
 984 Detection. ACS Sens 2, 1441-1451, doi:10.1021/acssensors.7b00333 (2017).
- 985 41 Brooke, J. S. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.
- 986 *Clin Microbiol Rev* **25**, 2-41, doi:10.1128/CMR.00019-11 (2012).
- Gao, H., Li, T., Feng, L. & Zhang, S. Elizabethkingia miricola Causes Intracranial
 Infection: A Case Study. *Front Med (Lausanne)* 8, 761924,
 doi:10.3389/fmed.2021.761924 (2021).
- 990 43 Gonzalez, C. *et al.* [Severe sepsis and pulmonary abscess with bacteremia due to
- 991 Elizabethkingia miricola]. *Med Mal Infect* 46, 49-51, doi:10.1016/j.medmal.2015.10.011
 992 (2016).

993	44	Green, O., Murray, P. & Gea-Banacloche, J. C. Sepsis caused by Elizabethkingia
994		miricola successfully treated with tigecycline and levofloxacin. Diagn Microbiol Infect
995		Dis 62, 430-432, doi:10.1016/j.diagmicrobio.2008.07.015 (2008).
996	45	Gupta, P., Zaman, K., Mohan, B. & Taneja, N. Elizabethkingia miricola: A rare non-
997		fermenter causing urinary tract infection. World J Clin Cases 5, 187-190,
998		doi:10.12998/wjcc.v5.i5.187 (2017).
999	46	Howard, J. C., Chen, K., Anderson, T. & Dalton, S. C. Elizabethkingia miricola
1000	-	bacteraemia in a haemodialysis patient. Access Microbiol 2, acmi000098,
1001		doi:10.1099/acmi.0.000098 (2020).
1002	47	Kalchev, Y., Petrova, A., Lengerova, G., Ivanov, I. & Murdjeva, M. Elizabethkingia
1003	• •	miricola Recovered from a Peritoneal Fluid Sample – A Clinical Case Report with
1005		Diagnostic Challenges. Open Access Macedonian Journal of Medical Sciences 10, 28-31,
1001		doi:10.3889/oamjms.2022.7716 (2022).
1005	48	Soler, E. <i>et al.</i> Elizabethkingia miricola: an opportunistic pathogen in ICU. <i>European</i>
1000	70	Journal of Public Health 32 , ckac131.406, doi:10.1093/eurpub/ckac131.406 (2022).
1007	49	Zdziarski, P., Paściak, M., Rogala, K., Korzeniowska-Kowal, A. & Gamian, A.
1008	49	
1009		Elizabethkingia miricola as an opportunistic oral pathogen associated with superinfectious complications in humoral immunodeficiency: a case report. <i>BMC</i>
1011	50	Infectious Diseases 17, 763, doi:10.1186/s12879-017-2886-7 (2017).
1012	50	Choi, M. H. <i>et al.</i> Risk Factors for Elizabethkingia Acquisition and Clinical
1013		Characteristics of Patients, South Korea. <i>Emerg Infect Dis</i> 25 , 42-51,
1014	7 1	doi:10.3201/eid2501.171985 (2019).
1015	51	Prevention, C. f. D. C. a. Pseudomonas aeruginosa in Healthcare Settings,
1016		< <u>https://www.cdc.gov/hai/organisms/pseudomonas.html</u> > (2019).
1017	52	Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO
1018		priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet Infectious
1019		Diseases 18, 318-327, doi: <u>https://doi.org/10.1016/S1473-3099(17)30753-3</u> (2018).
1020	53	Manner, C. et al. A genetic switch controls Pseudomonas aeruginosa surface
1021		colonization. Nat Microbiol 8, 1520-1533, doi:10.1038/s41564-023-01403-0 (2023).
1022	54	Lazarev, A., Hyun, J., Sanchez, J. L. & Verda, L. Community-Acquired Acinetobacter
1023		radioresistens Bacteremia in an Immunocompetent Host. Cureus 14, e29650,
1024		doi:10.7759/cureus.29650 (2022).
1025	55	Verma, R. & Baroco, A. L. Acinetobacter radioresistens Septicemia Associated With
1026		Pneumonia in a Patient With Chronic Obstructive Pulmonary Disease and Hepatitis C.
1027		Infectious Diseases in Clinical Practice 25, e12-e13, doi:10.1097/ipc.000000000000521
1028		(2017).
1029	56	Visca, P. et al. Community-acquired Acinetobacter radioresistens bacteremia in an HIV-
1030		positive patient. Emerg Infect Dis 7, 1032-1035, doi:10.3201/eid0706.010621 (2001).
1031	57	Wang, T., Costa, V., Jenkins, S. G., Hartman, B. J. & Westblade, L. F. Acinetobacter
1032		radioresistens infection with bacteremia and pneumonia. IDCases 15, e00495,
1033		doi:10.1016/j.idcr.2019.e00495 (2019).
1034	58	Poirel, L., Figueiredo, S., Cattoir, V., Carattoli, A. & Nordmann, P. Acinetobacter
1035		radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
1036		Antimicrob Agents Chemother 52, 1252-1256, doi:10.1128/AAC.01304-07 (2008).
1037	59	Rodriguez, R. L. et al. An ANI gap within bacterial species that advances the definitions
1038	-	of intra-species units. <i>mBio</i> 15, e0269623, doi:10.1128/mbio.02696-23 (2024).

- 103960Viver, T. *et al.* Towards estimating the number of strains that make up a natural bacterial1040population. Nat Commun 15, 544, doi:10.1038/s41467-023-44622-z (2024).
- Kotay, S., Chai, W., Guilford, W., Barry, K. & Mathers, A. J. Spread from the Sink to the
 Patient: In Situ Study Using Green Fluorescent Protein (GFP)-Expressing Escherichia
 coli To Model Bacterial Dispersion from Hand-Washing Sink-Trap Reservoirs. *Applied and environmental microbiology* 83, e03327-03316, doi:10.1128/AEM.03327-16 (2017).
- Langevin, S., Vincelette, J., Bekal, S. & Gaudreau, C. First case of invasive human
 infection caused by Cupriavidus metallidurans. *J Clin Microbiol* 49, 744-745,
 doi:10.1128/JCM.01947-10 (2011).
- Ranc, A., Dubourg, G., Fournier, P. E., Raoult, D. & Fenollar, F. Delftia tsuruhatensis, an
 Emergent Opportunistic Healthcare-Associated Pathogen. *Emerg Infect Dis* 24, 594-596,
 doi:10.3201/eid2403.160939 (2018).
- 105164Yin, Z. et al. Pan-Genome Analysis of Delftia tsuruhatensis Reveals Important Traits1052Concerning the Genetic Diversity, Pathogenicity, and Biotechnological Properties of the1053Species. Microbiol Spectr 10, e0207221, doi:10.1128/spectrum.02072-21 (2022).
- Hojgaard, S. M. M. *et al.* Characteristics and Outcomes of Patients with Delftia
 acidovorans Infections: a Retrospective Cohort Study. *Microbiol Spectr* 10, e0032622,
 doi:10.1128/spectrum.00326-22 (2022).
- Bilgin, H., Sarmis, A., Tigen, E., Soyletir, G. & Mulazimoglu, L. Delftia acidovorans: A
 rare pathogen in immunocompetent and immunocompromised patients. *Can J Infect Dis Med Microbiol* 26, 277-279, doi:10.1155/2015/973284 (2015).
- Khan, S., Sistla, S., Dhodapkar, R. & Parija, S. C. Fatal Delftia acidovorans infection in an immunocompetent patient with empyema. *Asian Pac J Trop Biomed* 2, 923-924, doi:10.1016/S2221-1691(12)60254-8 (2012).
- 106368Zhang, Z. et al. Assessment of global health risk of antibiotic resistance genes. Nat1064Commun 13, 1553, doi:10.1038/s41467-022-29283-8 (2022).
- 106569Kazama, H., Hamashima, H., Sasatsu, M. & Arai, T. Distribution of the antiseptic-1066resistance gene qacE Δ 1 in Gram-positive bacteria. *FEMS Microbiology Letters* 165, 295-1067299, doi:10.1111/j.1574-6968.1998.tb13160.x (1998).
- 106870Chen, Y. et al. Determining the susceptibility of carbapenem resistant Klebsiella1069pneumoniae and Escherichia coli strains against common disinfectants at a tertiary1070hospital in China. BMC Infect Dis 20, 88, doi:10.1186/s12879-020-4813-6 (2020).
- 1071 71 Pastrana-Carrasco, J. *et al.* [QacEdelta1 gene frequency and biocide resistance in
 1072 extended-spectrum beta-lactamase producing enterobacteriaceae clinical isolates]. *Rev*1073 *Invest Clin* 64, 535-540 (2012).
- Furi, L. *et al.* Evaluation of Reduced Susceptibility to Quaternary Ammonium
 Compounds and Bisbiguanides in Clinical Isolates and Laboratory-Generated Mutants of
 Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy* 57, 3488,
 doi:10.1128/AAC.00498-13 (2013).
- 1078 73 Hardy, K. *et al.* Increased Usage of Antiseptics Is Associated with Reduced
 1079 Susceptibility in Clinical Isolates of *Staphylococcus aureus*. *mBio* 9, e00894-00818,
 1080 doi:10.1128/mBio.00894-18 (2018).
- 1081 74 Liu, Q. *et al.* Frequency of biocide-resistant genes and susceptibility to chlorhexidine in high-level mupirocin-resistant, methicillin-resistant Staphylococcus aureus (MuH MRSA). *Diagn Microbiol Infect Dis* 82, 278-283,
- 1084 doi:10.1016/j.diagmicrobio.2015.03.023 (2015).

1085	75	Kroning, I. S. et al. New spa types, resistance to sanitisers and presence of efflux pump
1086		genes in Staphylococcus aureus from milk. International Dairy Journal 109, 104712,
1087		doi:https://doi.org/10.1016/j.idairyj.2020.104712 (2020).
1088	76	Alcock, B. P. et al. CARD 2023: expanded curation, support for machine learning, and
1089		resistome prediction at the Comprehensive Antibiotic Resistance Database. Nucleic Acids
1090		Res 51, D690-D699, doi:10.1093/nar/gkac920 (2023).
1091	77	Madden, T. The BLAST Sequence Analysis Tool. 16 (National Center for Biotechnology
1092		Information (US), 2003).
1093	78	Coenye, T., Spilker, T., Reik, R., Vandamme, P. & Lipuma, J. J. Use of PCR analyses to
1094		define the distribution of Ralstonia species recovered from patients with cystic fibrosis. J
1095		<i>Clin Microbiol</i> 43 , 3463-3466, doi:10.1128/JCM.43.7.3463-3466.2005 (2005).
1096	79	D'Inzeo, T. et al. Catheter-related bacteremia by Cupriavidus metallidurans. Diagn
1097		Microbiol Infect Dis 81, 9-12, doi:10.1016/j.diagmicrobio.2014.09.015 (2015).
1098	80	Velazquez, S. et al. From one species to another: A review on the interaction between
1099		chemistry and microbiology in relation to cleaning in the built environment. Indoor air
1100		29 , 880-894 (2019).
1101	81	FA, P. & DJ, F. Prevalence of gentamicin- and amikacin-resistant bacteria in sink drains.
1102		Journal of clinical microbiology 12, doi:10.1128/JCM.12.1.79-83.1980 (1980).
1103	82	MH, L., B, O., C, N., SA, K. & RA, W. Pseudomonas in the sinks in an intensive care
1104		unit: relation to patients. Journal of clinical pathology 37, doi:10.1136/jcp.37.4.424
1105		(1984).
1106	83	Rutala, W. A. & Weber, D. J. Water as a reservoir of nosocomial pathogens. Infect
1107		Control Hosp Epidemiol 18, 609-616 (1997).
1108	84	Cohen, N. R., Lobritz, M. A. & Collins, J. J. Microbial persistence and the road to drug
1109		resistance. Cell Host Microbe 13, 632-642, doi:10.1016/j.chom.2013.05.009 (2013).
1110	85	Hu, J. & Hartmann, E. M. Anthropogenic chemicals and their impacts on microbes living
1111		in buildings. <i>Microb Biotechnol</i> , doi:10.1111/1751-7915.13676 (2020).
1112	86	Lax, S. et al. Microbial and metabolic succession on common building materials under
1113		high humidity conditions. Nat Commun 10, 1767, doi:10.1038/s41467-019-09764-z
1114		(2019).
1115	87	Inkster, T., Walker, J. & Weinbren, M. Water-free patient care: a narrative review of the
1116		literature and discussion of the pressing need for a way forward. J Hosp Infect 152, 36-
1117		41, doi:10.1016/j.jhin.2024.06.006 (2024).
1118	88	Adams, R. I. et al. Passive dust collectors for assessing airborne microbial material.
1119		<i>Microbiome</i> 3 , 46, doi:10.1186/s40168-015-0112-7 (2015).
1120	89	Barberan, A. et al. The ecology of microscopic life in household dust. Proc Biol Sci 282,
1121		doi:10.1098/rspb.2015.1139 (2015).
1122	90	Emerson, J. B. et al. High temporal variability in airborne bacterial diversity and
1123		abundance inside single-family residences. Indoor Air 27, 576-586,
1124		doi:10.1111/ina.12347 (2017).
1125	91	Adams, C. E. & Dancer, S. J. Dynamic Transmission of Staphylococcus Aureus in the
1126		Intensive Care Unit. Int J Environ Res Public Health 17, doi:10.3390/ijerph17062109
1127		(2020).
1128	92	Kozajda, A., Jezak, K. & Kapsa, A. Airborne Staphylococcus aureus in different
1129		environments-a review. Environ Sci Pollut Res Int 26, 34741-34753,
1130		doi:10.1007/s11356-019-06557-1 (2019).

1131 1132	93	Shen, J., McFarland, A. G., Young, V. B., Hayden, M. K. & Hartmann, E. M. Toward Accurate and Robust Environmental Surveillance Using Metagenomics. <i>Frontiers in</i>
1132		Genetics 12, doi:10.3389/fgene.2021.600111 (2021).
1133	94	Shen, J. <i>et al.</i> An improved workflow for accurate and robust healthcare environmental
1135	<i>,</i>	surveillance using metagenomics. <i>Microbiome</i> 10 , 206, doi:10.1186/s40168-022-01412-x
1136		(2022).
1137	95	Skovgaard, S. et al. Recently introduced qacA/B genes in Staphylococcus epidermidis do
1138		not increase chlorhexidine MIC/MBC. J Antimicrob Chemother 68, 2226-2233,
1139		doi:10.1093/jac/dkt182 (2013).
1140	96	Crofts, T. S., McFarland, A. G. & Hartmann, E. M. Mosaic Ends Tagmentation (METa)
1141		Assembly for Highly Efficient Construction of Functional Metagenomic Libraries.
1142		<i>mSystems</i> 6, e0052421, doi:10.1128/mSystems.00524-21 (2021).
1143	97	Maillard, J. Y. & Pascoe, M. Disinfectants and antiseptics: mechanisms of action and
1144		resistance. Nat Rev Microbiol 22, 4-17, doi:10.1038/s41579-023-00958-3 (2024).
1145	98	Brauner, A., Fridman, O., Gefen, O. & Balaban, N. Q. Distinguishing between resistance,
1146		tolerance and persistence to antibiotic treatment. Nature Reviews Microbiology 14, 320-
1147		330, doi:10.1038/nrmicro.2016.34 (2016).
1148	99	Rhee, Y. et al. Relationship between chlorhexidine gluconate concentration and
1149		microbial colonization of patients' skin. Infect Control Hosp Epidemiol, 1-6,
1150	100	doi:10.1017/ice.2024.81 (2024).
1151	100	CLSI. (Clinical and Laboratory Standards Institute, Wayne, PA, 2018).
1152	101	Aftab, R., Dodhia, V. H., Jeanes, C. & Wade, R. G. Bacterial sensitivity to chlorhexidine
1153		and povidone-iodine antiseptics over time: a systematic review and meta-analysis of
1154	102	human-derived data. Scientific Reports 13, 347, doi:10.1038/s41598-022-26658-1 (2023).
1155 1156	102	Cowley, N. L. <i>et al.</i> Effects of Formulation on Microbicide Potency and Mitigation of the Development of Pactorial Insuscentibility. <i>Appl Environ Microbiol</i> 81 , 7330, 7338
1150		Development of Bacterial Insusceptibility. <i>Appl Environ Microbiol</i> 81 , 7330-7338, doi:10.1128/AEM.01985-15 (2015).
1157	103	de Frutos, M. <i>et al.</i> Serratia marcescens outbreak due to contaminated 2% aqueous
1158	105	chlorhexidine. Enferm Infecc Microbiol Clin 35 , 624-629,
1160		doi:10.1016/j.eimc.2016.06.016 (2017).
1160	104	Buxser, S. Has resistance to chlorhexidine increased among clinically-relevant bacteria?
1162	101	A systematic review of time course and subpopulation data. <i>PLOS ONE</i> 16 , e0256336,
1163		doi:10.1371/journal.pone.0256336 (2021).
1164	105	Kawamura-Sato, K., Wachino, J. I., Kondo, T., Ito, H. & Arakawa, Y. Correlation
1165		between reduced susceptibility to disinfectants and multidrug resistance among clinical
1166		isolates of Acinetobacter species. Journal of Antimicrobial Chemotherapy 65, 1975-1983,
1167		doi:10.1093/jac/dkq227 (2010).
1168	106	Lambert, R. J. W., Joynson, J. & Forbes, B. The relationships and susceptibilities of some
1169		industrial, laboratory and clinical isolates of pseudomonas aeruginosa to some antibiotics
1170		and biocides. Journal of Applied Microbiology 91, 972-984, doi:10.1046/j.1365-
1171		2672.2001.01460.x (2001).
1172	107	Lepainteur, M. et al. Prevalence of resistance to antiseptics and mupirocin among
1173		invasive coagulase-negative staphylococci from very preterm neonates in NICU: The
1174		creeping threat? Journal of Hospital Infection 83, 333-336,
1175		doi:10.1016/j.jhin.2012.11.025 (2013).

1176 108 Long, M. et al. Disinfectant susceptibility of different Salmonella serotypes isolated from 1177 chicken and egg production chains. Journal of Applied Microbiology 121, 672-681, 1178 doi:10.1111/jam.13184 (2016). 1179 109 Evans, H. L. et al. Effect of chlorhexidine whole-body bathing on hospital-acquired 1180 infections among trauma patients. Arch Surg 145, 240-246, doi:10.1001/archsurg.2010.5 1181 (2010). 1182 110 Climo, M. W. et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. 1183 N Engl J Med 368, 533-542, doi:10.1056/NEJMoa1113849 (2013). 1184 Arnold, B. et al. Review of Quaternary Ammonium Compounds: A Chemical Class of 111 1185 Emerging Concern. Environmental Science & Technology. 1186 Blaustein, R. A. et al. Toothbrush microbiomes feature a meeting ground for human oral 112 1187 and environmental microbiota. Microbiome 9, 32, doi:10.1186/s40168-020-00983-x 1188 (2021).1189 Shen, J. & Hartmann, E. M. Collect, extract, pool, and cultivate surface swab samples 113 1190 from built environments. Protocol Exchange, doi:10.21203/rs.3.pex-1656/v1 (2022). 1191 114 Edmiston, C. E., Jr. et al. Preoperative shower revisited: can high topical antiseptic levels 1192 be achieved on the skin surface before surgical admission? J Am Coll Surg 207, 233-239, 1193 doi:10.1016/j.jamcollsurg.2007.12.054 (2008). 1194 Gefter Shenderovich, J. et al. Chlorhexidine sustained-release varnishes for catheter 115 1195 coating - Dissolution kinetics and antibiofilm properties. Eur J Pharm Sci 112, 1-7, 1196 doi:10.1016/j.ejps.2017.10.041 (2018). 1197 116 West, A. M. et al. Surface area wiped, product type, and target strain impact bactericidal 1198 efficacy of ready-to-use disinfectant Towelettes. Antimicrob Resist Infect Control 7, 122, 1199 doi:10.1186/s13756-018-0416-z (2018). 1200 Hu, J. et al. Impacts of indoor surface finishes on bacterial viability. Indoor Air 29, 551-117 1201 562, doi:10.1111/ina.12558 (2019). 1202 Fridkin, S. K. Increasing prevalence of antimicrobial resistance in intensive care units. 118 1203 Crit Care Med 29, N64-68, doi:10.1097/00003246-200104001-00002 (2001). 1204 119 Kollef, M. H. & Fraser, V. J. Antibiotic resistance in the intensive care unit. Ann Intern 1205 Med 134, 298-314, doi:10.7326/0003-4819-134-4-200102200-00014 (2001). 1206 Hsu, T. et al. Urban Transit System Microbial Communities Differ by Surface Type and 120 1207 Interaction with Humans and the Environment. *mSystems* 1, doi:10.1128/mSystems.00018-16 (2016). 1208 1209 Rintala, H., Pitkaranta, M. & Taubel, M. Microbial communities associated with house 121 1210 dust. Adv Appl Microbiol 78, 75-120, doi:10.1016/B978-0-12-394805-2.00004-X (2012). 1211 Lax, S. et al. Bacterial colonization and succession in a newly opened hospital. Sci Transl 122 1212 Med 9, doi:10.1126/scitranslmed.aah6500 (2017). 1213 123 Huslage, K., Rutala, W. A., Sickbert-Bennett, E. & Weber, D. J. A quantitative approach 1214 to defining "high-touch" surfaces in hospitals. *Infect Control Hosp Epidemiol* **31**, 850-1215 853, doi:10.1086/655016 (2010). Schulster, L. M. et al. Guidelines for environmental infection control in health-care 1216 124 1217 facilities. Recommendations from CDC and the Healthcare Infection Control Practices 1218 Advisory Committee (HICPAC). (Chicago IL, 2004). 1219 Jinadatha, C. et al. Interaction of healthcare worker hands and portable medical 125 equipment: a sequence analysis to show potential transmission opportunities. BMC Infect 1220 1221 Dis 17, 800, doi:10.1186/s12879-017-2895-6 (2017).

1222	126	Cheng, V. C. <i>et al.</i> Hand-touch contact assessment of high-touch and mutual-touch
1223		surfaces among healthcare workers, patients, and visitors. <i>J Hosp Infect</i> 90 , 220-225,
1224 1225	107	doi:10.1016/j.jhin.2014.12.024 (2015).
1223	127	Xu, S. <i>et al.</i> Effects of the biocides on the culturable house dust-borne bacterial
1220		compositions and diversities. <i>Human and Ecological Risk Assessment: An International Journal</i> 22 , 1133-1146, doi:10.1080/10807039.2016.1143769 (2016).
1227	128	Lederberg, J. & Lederberg, E. M. Replica plating and indirect selection of bacterial
1228	120	mutants. <i>J Bacteriol</i> 63 , 399-406, doi:10.1128/JB.63.3.399-406.1952 (1952).
122)	129	McFarland, A. G. <i>et al.</i> Triclosan Tolerance Is Driven by a Conserved Mechanism in
1230	12)	Diverse Pseudomonas Species. Applied and Environmental Microbiology 87,
1231		doi:10.1128/aem.02924-20 (2021).
1232	130	Andrews, S. et al. FastQC: a quality control tool for high throughput sequence data,
1233	150	< <u>http://www.bioinformatics.babraham.ac.uk/projects/fastqc</u> > (2016).
1235	131	Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor.
1235	101	<i>Bioinformatics</i> 34 , i884-i890, doi:10.1093/bioinformatics/bty560 (2018).
1237	132	Bankevich, A. <i>et al.</i> SPAdes: a new genome assembly algorithm and its applications to
1238		single-cell sequencing. J Comput Biol 19, 455-477, doi:10.1089/cmb.2012.0021 (2012).
1239	133	Parks, D. H., Imelfort, M., Skennerton, C. T., Hugenholtz, P. & Tyson, G. W. CheckM:
1240		assessing the quality of microbial genomes recovered from isolates, single cells, and
1241		metagenomes. Genome Res 25, 1043-1055, doi:10.1101/gr.186072.114 (2015).
1242	134	Gurevich, A., Saveliev, V., Vyahhi, N. & Tesler, G. QUAST: quality assessment tool for
1243		genome assemblies. Bioinformatics 29, 1072-1075, doi:10.1093/bioinformatics/btt086
1244		(2013).
1245	135	Ramsin, C. (2022).
1246	136	Clausen, P., Aarestrup, F. M. & Lund, O. Rapid and precise alignment of raw reads
1247		against redundant databases with KMA. BMC Bioinformatics 19, 307,
1248		doi:10.1186/s12859-018-2336-6 (2018).
1249	137	Larsen, M. V. et al. Benchmarking of methods for genomic taxonomy. J Clin Microbiol
1250		52 , 1529-1539, doi:10.1128/JCM.02981-13 (2014).
1251	138	Hasman, H. et al. Rapid whole-genome sequencing for detection and characterization of
1252		microorganisms directly from clinical samples. J Clin Microbiol 52, 139-146,
1253		doi:10.1128/JCM.02452-13 (2014).
1254	139	Asnicar, F. et al. Precise phylogenetic analysis of microbial isolates and genomes from
1255		metagenomes using PhyloPhlAn 3.0. Nat Commun 11, 2500, doi:10.1038/s41467-020-
1256		16366-7 (2020).
1257	140	Alanjary, M., Steinke, K. & Ziemert, N. AutoMLST: an automated web server for
1258		generating multi-locus species trees highlighting natural product potential. <i>Nucleic Acids</i>
1259		<i>Res</i> 47 , W276-W282, doi:10.1093/nar/gkz282 (2019).
1260	141	Rodriguez, R. L. et al. The Microbial Genomes Atlas (MiGA) webserver: taxonomic and
1261		gene diversity analysis of Archaea and Bacteria at the whole genome level. <i>Nucleic Acids</i>
1262	140	<i>Res</i> 46 , W282-W288, doi:10.1093/nar/gky467 (2018).
1263	142	Sievers, F. & Higgins, D. G. Clustal Omega for making accurate alignments of many
1264	142	protein sequences. Protein Sci 27, 135-145, doi:10.1002/pro.3290 (2018).
1265 1266	143	Camargo, A. P. <i>et al.</i> Identification of mobile genetic elements with geNomad. <i>Nat Biotechnol</i> , doi:10.1038/s41587-023-01953-y (2023).
1200		Dioiecinioi, uoi.10.1050/8+150/-025-01755-y (2025).

1267	144	Johansson, M. H. K. et al. Detection of mobile genetic elements associated with
1268		antibiotic resistance in Salmonella enterica using a newly developed web tool:
1269		MobileElementFinder. J Antimicrob Chemother 76, 101-109, doi:10.1093/jac/dkaa390
1270		(2021).
1271	145	Wang, M. et al. VRprofile2: detection of antibiotic resistance-associated mobilome in
1272		bacterial pathogens. Nucleic Acids Res 50, W768-W773, doi:10.1093/nar/gkac321
1273		(2022).
1274	146	Maciel-Guerra, A. et al. Dissecting microbial communities and resistomes for
1275		interconnected humans, soil, and livestock. ISME J 17, 21-35, doi:10.1038/s41396-022-
1276		01315-7 (2023).
1277	147	Team, R. C. R: A language and environment for statistical computing. (2013).
1278	148	Wickham, H., François, R., Henry, L. & Müller, K. dplyr: A Grammar of Data
1279		<i>Manipulation</i> , < <u>https://dplyr.tidyverse.org</u> > (2022).
1280	149	Wickham, H. stringr: Simple, consistent wrappers for common string operations,
1281		< <u>https://stringr.tidyverse.org</u> > (2023).
1282	150	Kassambara, A. rstatix: Pipe-friendly framework for basic statistical tests,
1283		< <u>https://rpkgs.datanovia.com/rstatix/</u> > (2023).
1284	151	Wickham, H. ggplot2: Elegant Graphics for Data Analysis. (Springer-Verlag New York,
1285		2016).
1286	152	Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in
1287		multidimensional genomic data. <i>Bioinformatics</i> 32 , 2847-2849,
1288		doi:10.1093/bioinformatics/btw313 (2016).
1289	153	Wilkins, D. gggenes: Draw gene arrow maps in 'ggplot2', < <u>https://CRAN.R-</u>
1290		project.org/package=gggenes> (2020).

1291